BRCA1 Gene

Aliases
for BRCA1 gene

Previous GC identifers: GC17P062255 GC17M043361 GC17M041105 GC17M041569 GC17M038450 GC17M036962

Summaries
for BRCA1 gene

Genomic Views
for BRCA1 gene

RefSeq DNA sequence:

NC_000017.10  NC_018928.1  NT_010783.15  

SwitchGear Promoter luciferase reporter plasmid: BRCA1 promoter sequence

QIAGEN PyroMark CpG Assay predesigned Pyrosequencing DNA Methylation assays in human, mouse, rat BRCA1

BRCA1 Gene in genomic location: bands according to Ensembl, locations according to (and/or Entrez Gene and/or Ensembl if different)


GeneLoc information about chromosome 17         GeneLoc Exon Structure

GeneLoc location for GC17M041197:  view genomic region     (about GC identifiers)

Proteins
for BRCA1 gene

6/20 PDB 3D structures from and Proteopedia for BRCA1 (see all 20):

1JM7 (3D)        1JNX (3D)        1N5O (3D)        1OQA (3D)        1T15 (3D)        1T29 (3D)    

Explore the universe of human proteins at neXtProt for BRCA1: NX_P38398

Post-translational modifications:

	Browse Purified and Recombinant Proteins at EMD Millipore
	Browse R&D Systems for human recombinant proteins
	Browse recombinant and purified proteins available from Enzo Life Sciences
	Browse OriGene full length recombinant human proteins expressed in human HEK293 cells Browse OriGene Protein Over-expression Lysates OriGene Custom Protein Services for BRCA1
	GenScript Custom Purified and Recombinant Proteins Services for BRCA1
	Novus Biologicals BRCA1 Protein
	Browse Sino Biological Recombinant Proteins
	Browse ProSpec Recombinant Proteins
	Uscn Proteins for BRCA1

Gene Ontology (GO): 5/17 cellular component terms (GO ID links to tree view) (see all 17):    About this table

	EMD Millipore Mono- and Polyclonal Antibodies for the study of BRCA1
	R&D Systems Antibodies for BRCA1
	Cell Signaling Technology (CST) Antibodies for BRCA1
	OriGene Antibodies (see all 6): BRCA1 OriGene Custom Antibody Services for BRCA1
	GenScript Superior Antibodies for BRCA1
	Novus Biologicals BRCA1 Antibodies
	Abcam antibodies for BRCA1
	Uscn Antibodies for BRCA1
	ThermoFisher Antibodies for BRCA1

	EMD Millipore Kits and Assays for the Analysis of BRCA1
	OriGene Custom Immunoassay Development Browse OriGene Fluorogenic Cell Assay Kits
	Browse R&D Systems for biochemical assays
	GenScript Custom Assay Services for BRCA1
	Browse Enzo Life Sciences for kits & assays
	Uscn ELISAs and CLIAs for BRCA1

Protein Domains /
Families
for BRCA1 gene

ProtoNet protein and cluster: P38398

Function
for BRCA1 gene

     Gene Ontology (GO): 5/12 molecular function terms (GO ID links to tree view) (see all 12):    About this table

15/23 MGI mutant phenotypes (inferred from 18 alleles) (MGI details for Brca1)

inGenious Targeting Laboratory - Customizable classic, inducible, and humanized mouse model solutions for BRCA1

miRNA Products:		miRTarBase miRNAs that target BRCA1: hsa-mir-146a (MIRT001920), hsa-mir-24 (MIRT004836), hsa-mir-15a (MIRT003333), hsa-mir-16 (MIRT003328), hsa-mir-212 (MIRT003967)
		OriGene 3'-UTR Clone (see all 5): BRCA1 Browse MicroRNA Expression Plasmids
		QIAGEN Custom miScript Target Protector blocks miRNA-binding site of human, mouse, rat BRCA1
		8/30 QIAGEN miScript miRNA Assays for microRNAs that regulate BRCA1 (see all 30):
		hsa-miR-4291 hsa-miR-3934 hsa-miR-520d-5p hsa-miR-125a-3p hsa-miR-522 hsa-miR-944 hsa-miR-450b-3p hsa-miR-132
		SwitchGear 3'UTR luciferase reporter plasmid: BRCA1 3' UTR sequence

Inhib. RNA Products:		EMD Millipore RNAi Products for the Analysis of BRCA1 Gene knock-down
		OriGene 29mer shRNA kits in GFP-retroviral vector in human, mouse, rat for BRCA1 (see all 7) OriGene shRNA RFP: BRCA1 OriGene siRNA: BRCA1
		QIAGEN FlexiTube/FlexiPlate siRNA for gene silencing in human, mouse, rat BRCA1
		Sirion Biotech Custom design and validation of potent shRNA sequences against BRCA1

Gene Editing Products:			DNA2.0 Custom Protein Engineering Service for BRCA1
			Sirion Biotech Customized adenovirus for overexpression of BRCA1  Sirion Biotech Customized adenovirus for potent knockdown of BRCA1

Clone Products:		Browse Clones for the Expression of Recombinant Proteins Available from EMD Millipore
		OriGene Myc/DDK tagged cDNA clones in CMV expression vector in human, mouse, rat for BRCA1 (see all 10) OriGene untagged cDNA clones in CMV expression vector in human, mouse, rat for BRCA1 (see all 8) OriGene custom cloning services - gene synthesis, subcloning, mutagenesis, variant library, vector shuttling
		GenScript: all cDNA clones in your preferred vector (see all 5): BRCA1 (NM_007294)
		Browse Sino Biological Human cDNA Clones
		DNA2.0 Custom Codon Optimized Gene Synthesis Service for BRCA1
		Vector BioLabs ready-to-use adenovirus/AAV for human, mouse, rat BRCA1

Cell Line Products:		GenScript Custom overexpressing Cell Line Services for BRCA1
		Search LifeMap BioReagents cell lines for BRCA1
		Sirion Biotech Customized stable knockdown cell line services for BRCA1  Sirion Biotech Customized inducible knockdown cell line services for BRCA1

In Situ Assay Products:

Advanced Cell Diagnostics RNAscope RNA in situ hybridization assays for BRCA1

Pathways & Interactions
for BRCA1 gene

	Super-pathway	contained gene-specific pathways
1	Meiotic Synapsis	Meiotic Synapsis 1.00 Chromosome Maintenance 0.56 Meiosis 0.70 Meiotic Recombination 0.32
2	Recruitment of repair and signaling proteins to double-strand breaks	Recruitment of repair and signaling proteins to double-strand breaks 1.00 ATM mediated phosphorylation of repair proteins 0.62 ATM mediated response to DNA double-strand break 0.62
3	Homologous Recombination Repair	Homologous Recombination Repair 1.00 Double-Strand Break Repair 0.71 Homologous recombination repair of replication-independent double-strand breaks 1.00
4	Fanconi Anemia pathway	Fanconi Anemia pathway 1.00 BARD1 signaling events 0.23 Fanconi's Anaemia Pathway 0.43
5	Chks in Checkpoint Regulation	Chks in Checkpoint Regulation 1.00 DNA Repair Mechanisms 0.32 p53 Signaling 0.32

5/10 EMD Millipore Pathways for BRCA1

	DNA damage ATM/ATR regulation of G1/S checkpoint
	Development VEGF signaling and activation
	Meiosis
	Cell cycle Regulation of G1/S transition (part 1)
	DNA damage DNA-damage-induced responses

5/11 Downloadable PowerPoint Slides of QIAGEN Pathway Central Maps for BRCA1

	BRCA1 Pathway
	Molecular Mechanisms of Cancer
	JAK-STAT Pathway
	Estrogen Pathway
	DNA Damage Induced 14-3-3Sigma Signaling

2 Cell Signaling Technology (CST) Pathways for BRCA1

	Cell Cycle / Checkpoint Control
	DNA Damage

5/8 GeneGo (Thomson Reuters) Pathways for BRCA1

	DNA damage Role of Brca1 and Brca2 in DNA repair
	DNA damage ATM/ATR regulation of G1/S checkpoint
	DNA damage NHEJ mechanisms of DSBs repair
	Cell cycle Transition and termination of DNA replication
	Cell cycle Regulation of G1/S transition (part 1)

5/14 BioSystems Pathways for BRCA1

	Integrated Breast Cancer Pathway
	DNA damage response
	Signaling Pathways in Glioblastoma
	Integrated Pancreatic Cancer Pathway
	Integrated Pancreatic Cancer Pathway

5/15        Reactome Pathways for BRCA1

	ATM mediated response to DNA double-strand break
	DNA Repair
	Homologous recombination repair of replication-independent double-strand breaks
	Recruitment of repair and signaling proteins to double-strand breaks
	ATM mediated phosphorylation of repair proteins

1         Kegg Pathway  (Kegg details for BRCA1)

Ubiquitin mediated proteolysis

BRCA1 for pathways           About GeneDecksing

Interactions:

    SABiosciences Gene Network Central^TM Interacting Genes and Proteins Network for BRCA1

STRING Interaction Network Preview (showing 5 interactants - click image to see 25)

5/362 Interacting proteins for BRCA1 (P38398^{1, 2, 3} ENSP00000350283⁴) via UniProtKB, MINT, STRING, and/or I2D (see all 362)

Gene Ontology (GO): 5/48 biological process terms (GO ID links to tree view) (see all 48):    About this table

Drugs & Compounds
for BRCA1 gene

Transcripts
for BRCA1 gene

Expression
for BRCA1 gene

BRCA1 expression in normal human tissues (normalized intensities)
See probesets specificity/sensitivity at GeneAnnot
About this imageBioGPS
CGAP TAG: --

About this image

BRCA1 expression in embryonic tissues and stem cells
Expression by the Database of Embryonic development, Stem cell research, and Regenerative medicine    About this table

1 LifeMap In Vivo Development Anatomical Compartment/Cell
	Tissue Anatomical Compartment Cell			Category (developmental path)
	TestisSeminiferous TubulesPrimary Spermatocyte			Germ Cells, Male Gametocytes
Expression: Positive    Negative     Selective marker Experimental details: Curated     Microarrays     In-situ hybridization

Primer Products:		OriGene genome-wide validated SYBR primer pairs in human, mouse, rat for BRCA1 Browse OriGene validated miRNA SYBR primer pairs
		SABiosciences RT2 qPCR Primer Assay in human, mouse, rat BRCA1
		QIAGEN QuantiTect SYBR Green Assays in human, mouse, rat BRCA1
		QIAGEN QuantiFast Probe-based Assays in human, mouse, rat BRCA1

In Situ Assay Products:

Advanced Cell Diagnostics RNAscope RNA in situ hybridization assays for BRCA1

Orthologs
for BRCA1 gene

Paralogs
for BRCA1 gene

Genomic Variants
for BRCA1 gene

10/2951 NCBI SNPs in BRCA1 are shown (see all 2951)     About this table

Genomic Data					Transcription Related Data				Allele Frequencies
SNP ID	Valid	Clinical significance	Chr 17 pos	Sequence	#	AA Chg	Type	More	#	Allele freq	Pop	Total sample	More
-1st2nd3rd	-1st2nd3rd	-1st2nd3rd	-1st2nd3rd	--	--	--	-1st2nd3rd	--	--	-1st2nd3rd	-1st2nd3rd	-1st2nd3rd
rs2018669971,2	C	untested	37284997(+)	AACACA/GTTAGA	6	--	int1 us2k1		0	--	--	--	--
rs803571111,2	C	untested	37285027(-)	AGAAAC/G/TGGATT	16	T R M	mis1 ut51		0	--	--	--	--
rs803569291,2	C	untested	37285078(-)	TGCTAA/C/TGCAGA	16	K T M	mis1 ut51		0	--	--	--	--
rs803580101,2	C	untested	37285106(-)	ATCTGA/C/G/T          TAAGT	6	--	spd1		0	--	--	--	--
rs1932144691,2	C	untested	37293197(+)	AATGTC/TTGCTG	6	--	int1		0	--	--	--	--
rs563280131,2	C	untested	37293334(-)	CCCCCA/C/GCTACC	6	--	int1		0	--	--	--	--
rs803580551,2	C	untested	37293335(-)	CCCCCC/GTACCC	6	--	int1		0	--	--	--	--
rs803568801,2	C	untested	37293376(-)	CTCCAA/C/GAAAGT	15	K T R	mis1 int1		0	--	--	--	--
rs18000621,2	C,F,H	untested	37293380(-)	ACAAAA/G/TTGTGA	15	K N	syn1 mis1 int1		10		NS EA NA	1074
rs803571641,2	C	untested	37293381(-)	CAAAGA/C/TGTGAC	15	S R C	mis1 int1		0	--	--	--	--

HapMap Linkage Disequilibrium report for BRCA1 (41196312 - 41322290 bp)
Structural Variations (Copy Number Variations, Insertions/Deletions, Inversions)
      Database of Genomic Variants (DGV) variations for BRCA1: --
Human Gene Mutation Database (HGMD): BRCA1

Locus Specific Mutation Databases (LSDB): BRCA1

3 SABiosciences Cancer Mutation PCR Assays for BRCA1: Cosmic Id AA Change 23943 p.V757fs*8 23941 p.? 13841 p.L30F

QIAGEN SeqTarget long-range PCR primers in human, mouse, rat for resequencing BRCA1

DNA2.0 Custom Variant and Variant Library Synthesis for BRCA1

Disorders / Diseases
for BRCA1 gene

20/125 diseases for BRCA1

10/95 Novoseek disease relationships for BRCA1 gene (see all 95)    About this table

Publications
for BRCA1 gene

PubMed articles for BRCA1 gene, integrated from 9 sources (see all 2966) (see top 10): (articles sorted by number of sources associating them with BRCA1)

Utopia: connect your pdf to the dynamic world of online information

1. One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in Southern Sweden. (PubMed id 14746861)^{1, 2, 4, 9} Malander S.... Borg A. (2004)
2. A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes. (PubMed id 11857015)^{1, 4, 9} Antoniou A.C....Easton D.F. (2002)
3. [Mutational analysis of BRCA1 and BRCA2 genes in early-onset breast cancer patients in Shanghai] (PubMed id 16324400)^{1, 4, 9} Song C.G....Shao Z.M. (2005)
4. Novel germline mutations in the BRCA1 and BRCA2 genes in Indian breast and breast-ovarian cancer families. (PubMed id 14722926)^{1, 2, 9} Valarmathi M.T.... Das S.N. (2004)
5. Germline BRCA1 mutations predispose to pancreatic adenocarcinoma. (PubMed id 18762988)^{1, 2, 9} Al-Sukhni W....Gallinger S. (2008)
6. Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1. (PubMed id 15256476)^{1, 4, 9} Bau D.T....Shen C.Y. (2004)
7. Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. (PubMed id 11114888)^{1, 2, 9} Tibbetts R.S.... Abraham R.T. (2000)
8. [Germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in China Han people] (PubMed id 15059511)^{1, 4, 9} Zhou Y.Z....Fang F.D. (2004)
9. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. (PubMed id 14680495)^{1, 4, 9} Robson M.E....Foulkes W.D. (2004)
10. BACH1, a novel helicase-like protein, interacts directly with BRCA1 and contributes to its DNA repair function. (PubMed id 11301010)^{1, 2, 9} Cantor S.B....Livingston D.M. (2001)
11. [Population genetic analysis of the association between the BRCA1 and P53 gene polymorphisms and the risk of sporadic breast cancer] (PubMed id 16161633)^{1, 4, 9} Tarasov V.A....Mel'nik V.A. (2005)
12. BRCA1 : BARD1 induces the formation of conjugated ubiquitin structures, dependent on K6 of ubiquitin, in cells during DNA replication and repair. (PubMed id 14976165)^{1, 2, 9} Morris J.R. and Solomon E. (2004)
13. Association between BRCA1 mutations and ratio of female to male births in offspring of families with breast cancer, ovarian cancer, or both. (PubMed id 12928470)^{1, 4, 9} de la Hoya M....Caldes T. (2003)
14. High proportion of missense mutations of the BRCA1 and BRCA2 genes in Japanese breast cancer families. (PubMed id 9609997)^{1, 2, 9} Katagiri T.... Miki Y. (1998)
15. BRCA1, BRCA2 and CHEK2 (1100 del C) germline mutations in hereditary breast and ovarian cancer families in South India. (PubMed id 14507240)^{1, 4, 9} Rajkumar T....Shanta V. (2003)
16. A high proportion of mutations in the BRCA1 gene in German breast/ovarian cancer families with clustering of mutations in the 3' third of the gene. (PubMed id 9760198)^{1, 2, 9} Dong J....Royer-Pokora B. (1998)
17. Comparison of BRCA1 polymorphisms, rare sequence variants and/or missense mutations in unaffected and breast/ovarian cancer populations. (PubMed id 8776600)^{1, 2, 9} Durocher F.... Simard J. (1996)
18. BRCA1 R841W: a strong candidate for a common mutation with moderate phenotype. (PubMed id 8968716)^{1, 2, 9} Barker D.F.... Anton-Culver H. (1996)
19. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. (PubMed id 7545954)^{1, 2, 9} Miki Y.... Skolnick M.H. (1994)
20. BRCA1 affects lipid synthesis through its interaction with acetyl-CoA carboxylase. (PubMed id 16326698)^{1, 2, 9} Moreau K.... Venezia N.D. (2006)
21. Breast cancer predisposing alleles in Poland. (PubMed id 15980987)^{1, 4, 9} Gorski B....Lubinski J. (2005)
22. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. (PubMed id 14709740)^{1, 4, 9} Kirchhoff T....Offit K. (2004)
23. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. (PubMed id 14709734)^{1, 4, 9} Niell B.L....Gruber S.B. (2004)
24. The Norwegian founder mutations in BRCA1: high penetrance confirmed in an incident cancer series and differences observed in the risk of ovarian cancer. (PubMed id 14522380)^{1, 4, 9} Heimdal K....Moller P. (2003)
25. A single nucleotide polymorphism in the RAD51 gene modifies cancer risk in BRCA2 but not BRCA1 carriers. (PubMed id 11248061)^{1, 4, 9} Levy-Lahad E....Gershoni-Baruch R. (2001)
26. Structure of a BRCA1-BARD1 heterodimeric RING-RING complex. (PubMed id 11573085)^{1, 2, 9} Brzovic P.S....Klevit R.E. (2001)
27. A high incidence of BRCA1 mutations in 20 breast-ovarian cancer families. (PubMed id 8554067)^{1, 2, 9} Serova O.... Lenoir G.M. (1996)
28. Structural evidence for direct interactions between the BRCT domains of human BRCA1 and a phospho-peptide from human ACC1. (PubMed id 18452305)^{1, 2, 9} Shen Y. and Tong L. (2008)
29. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. (PubMed id 17525340)^{1, 2, 9} Wang B....Elledge S.J. (2007)
30. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development. (PubMed id 15726604)^{1, 4, 9} Koren-Michowitz M....Amariglio N. (2005)
31. Breast cancer risk in BRCA1 and BRCA2 mutation carriers and polyglutamine repeat length in the AIB1 gene. (PubMed id 15900600)^{1, 4, 9} Hughes D.J....Sinilnikova O.M. (2005)
32. Polyglutamine repeat length in the AIB1 gene modifies breast cancer susceptibility in BRCA1 carriers. (PubMed id 14648706)^{1, 4, 9} Kadouri L....Eeles R.A. (2004)
33. A single-nucleotide polymorphism in the RAD51 gene modifies breast cancer risk in BRCA2 carriers, but not in BRCA1 carriers or noncarriers. (PubMed id 15138485)^{1, 4, 9} Kadouri L....Peretz T. (2004)
34. Study design: evaluating gene-environment interactions in the etiology of breast cancer - the WECARE study. (PubMed id 15084244)^{1, 4, 9} Bernstein J.L....Thompson W.D. (2004)
35. Kin-cohort estimates for familial breast cancer risk in relation to variants in DNA base excision repair, BRCA1 interacting and growth factor genes. (PubMed id 15113441)^{1, 4, 9} Sigurdson A.J....Struewing J.P. (2004)
36. The BRCA1/BARD1 heterodimer assembles polyubiquitin chains through an unconventional linkage involving lysine residue K6 of ubiquitin. (PubMed id 12890688)^{1, 2, 9} Wu-Baer F....Baer R. (2003)
37. Regulation of BRCC, a holoenzyme complex containing BRCA1 and BRCA2, by a signalosome-like subunit and its role in DNA repair. (PubMed id 14636569)^{1, 2, 9} Dong Y.... Shiekhattar R. (2003)
38. Breast cancer risk reduction associated with the RAD51 polymorphism among carriers of the BRCA1 5382insC mutation in Poland. (PubMed id 12750242)^{1, 4, 9} Jakubowska A....Lubinski J. (2003)
39. BRCA1-independent ubiquitination of FANCD2. (PubMed id 12887909)^{1, 2, 9} Vandenberg C.J....Patel K.J. (2003)
40. BRCA1 regulates the G2/M checkpoint by activating Chk1 kinase upon DNA damage. (PubMed id 11836499)^{1, 2, 9} Yarden R.I.... Brody L.C. (2002)
41. BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains. (PubMed id 12360400)^{1, 2, 9} Magnard C.... Venezia N.D. (2002)
42. Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptives. (PubMed id 11668223)^{1, 4, 9} Runnebaum I.B....Narod S.A. (2001)
43. A single nucleotide polymorphism in the 5' untranslated region of RAD51 and risk of cancer among BRCA1/2 mutation carriers. (PubMed id 11535547)^{1, 4, 9} Wang W.W.... Struewing J.P. (2001)
44. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. (PubMed id 11239454)^{1, 2, 9} Garcia-Higuera I.... D'Andrea A.D. (2001)
45. [Clinical and pathological characteristics and clinical course of patients with breast cancer and BRCA1/BRCA2 mutations] (PubMed id 11481082)^{1, 4, 9} Pericay C....Alonso C. (2001)
46. A high occurrence of BRCA1 and BRCA2 mutations among Czech hereditary breast and breast-ovarian cancer families. (PubMed id 11192759)^{1, 4, 9} Machackova E....Messiaen L. (2000)
47. Localization of BRCA1 and a splice variant identifies the nuclear localization signal. (PubMed id 8972225)^{1, 2, 9} Thakur S.... Weber B.L. (1997)
48. Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1. (PubMed id 8938427)^{1, 2, 9} Smith T.M.... King M.-C. (1996)
49. Mutations in the BRCA1 gene in Japanese breast cancer patients. (PubMed id 8723683)^{1, 2, 9} Katagiri T.... Nakamura Y. (1996)
50. Mutations in the BRCA1 gene in families with early-onset breast and ovarian cancer. (PubMed id 7894491)^{1, 2, 9} Castilla L.H.... Weber B.L. (1994)
51. KIAA0101 interacts with BRCA1 and regulates centrosom e number. (PubMed id 21673012)^{1, 2} Kais Z....Parvin J.D. (2011)
52. The UBXN1 protein associates with autoubiquitinated f orms of the BRCA1 tumor suppressor and inhibits its enzymatic function. (PubMed id 20351172)^{1, 2} Wu-Baer F....Baer R. (2010)
53. Comparison of the structures and peptide binding spec ificities of the BRCT domains of MDC1 and BRCA1. (PubMed id 20159462)^{1, 2} Campbell S.J....Glover J.N. (2010)
54. The CHK2-BRCA1 tumour suppressor pathway ensures chro mosomal stability in human somatic cells. (PubMed id 20364141)^{1, 2} Stolz A....Bastians H. (2010)
55. Detection of splicing aberrations caused by BRCA1 and BRCA2 sequence variants encoding missense substitutions: implications for prediction of pathogenicity. (PubMed id 20513136)^{1, 2} Walker L.C....Spurdle A.B. (2010)
56. MERIT40 controls BRCA1-Rap80 complex integrity and recruitment to DNA double-strand breaks. (PubMed id 19261746)^{1, 2} Shao G.... Greenberg R.A. (2009)
57. NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. (PubMed id 19261749)^{1, 2} Wang B.... Elledge S.J. (2009)
58. MERIT40 facilitates BRCA1 localization and DNA damage repair. (PubMed id 19261748)^{1, 2} Feng L.... Chen J. (2009)
59. PALB2 is an integral component of the BRCA complex re quired for homologous recombination repair. (PubMed id 19369211)^{1, 2} Sy S.M....Chen J. (2009)
60. Pathogenicity of the BRCA1 missense variant M1775K is determined by the disruption of the BRCT phosphopeptide-binding pocket: a multi-modal approach. (PubMed id 18285836)^{1, 2} Tischkowitz M....Foulkes W.D. (2008)
61. CCDC98 targets BRCA1 to DNA damage sites. (PubMed id 17643121)^{1, 2} Liu Z.... Yu X. (2007)
62. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. (PubMed id 17525332)^{1, 2} Matsuoka S.... Elledge S.J. (2007)
63. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. (PubMed id 17924331)^{1, 2} Easton D.F....Goldgar D.E. (2007)
64. CCDC98 is a BRCA1-BRCT domain-binding protein involved in the DNA damage response. (PubMed id 17643122)^{1, 2} Kim H.... Chen J. (2007)
65. Global, in vivo, and site-specific phosphorylation dynamics in signaling networks. (PubMed id 17081983)^{1, 2} Olsen J.V....Mann M. (2006)
66. BRCA1 ubiquitinates its phosphorylation-dependent binding partner CtIP. (PubMed id 16818604)^{1, 2} Yu X....Chen J. (2006)
67. ACCA phosphopeptide recognition by the BRCT repeats of BRCA1. (PubMed id 16698035)^{1, 2} Ray H.... Venezia N.D. (2006)
68. A haplotype-based case-control study of BRCA1 and sporadic breast cancer risk. (PubMed id 16103107)^{1, 4} Freedman M.L....Haiman C.A. (2005)
69. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. (PubMed id 16049805)^{1, 4} Kotsopoulos J....Narod S.A. (2005)
70. Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain. (PubMed id 14729053)^{1, 4} Rodriguez J.A....Henderson B.R. (2004)
71. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer. (PubMed id 15104281)^{1, 4} Cavalli L.R....Haddad B.R. (2004)
72. BRCA1 and BRCA2 germline mutation spectrum and frequencies in Belgian breast/ovarian cancer families. (PubMed id 15026808)^{1, 2} Claes K.... Messiaen L. (2004)
73. Artemis is a phosphorylation target of ATM and ATR and is involved in the G2/M DNA damage checkpoint response. (PubMed id 15456891)^{1, 2} Zhang X....Legerski R.J. (2004)
74. A gene-environment interaction between occupation and BRCA1/BRCA2 mutations in male breast cancer? (PubMed id 15519522)^{1, 4} Palli D....Ottini L. (2004)
75. Human claspin works with BRCA1 to both positively and negatively regulate cell proliferation. (PubMed id 15096610)^{1, 2} Lin S.-Y.... Elledge S.J. (2004)
76. Accommodating risk: responses to BRCA1/2 genetic testing of women who have had cancer. (PubMed id 15144764)^{1, 4} Hallowell N....Watson M. (2004)
77. Association of NQO1 polymorphism with spontaneous breast cancer in two independent populations. (PubMed id 15138483)^{1, 4} Menzel H.J....Kraft H.G. (2004)
78. An audit of screening for familial breast cancer before 50 years in the South Thames Region - have we got it right? (PubMed id 15131403)^{1, 4} Murday V....Hodgson S. (2004)
79. Structure and mechanism of BRCA1 BRCT domain recognition of phosphorylated BACH1 with implications for cancer. (PubMed id 15133502)^{1, 2} Clapperton J.A....Smerdon S.J. (2004)
80. [Analysis of BRCA1 mutations in Chinese patients with early onset breast cancer and affected relatives.] (PubMed id 15777502)^{1, 4} Hu Z....Shao Z.M. (2004)
81. BRCA1 and BRCA2 germline mutations in Korean patients with sporadic breast cancer. (PubMed id 15365993)^{1, 2} Seo J.H.... Koo B.H. (2004)
82. BRCA1 phosphorylation by Aurora-A in the regulation of G2 to M transition. (PubMed id 14990569)^{1, 2} Ouchi M.... Ouchi T. (2004)
83. Long-term psychological impact of carrying a BRCA1/2 mutation and prophylactic surgery: a 5-year follow-up study. (PubMed id 14551306)^{1, 4} van Oostrom I....Tibben A. (2003)
84. Structural consequences of a cancer-causing BRCA1-BRCT missense mutation. (PubMed id 12427738)^{1, 2} Williams R.S. and Glover J.N. (2003)
85. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families in Southern Germany. (PubMed id 12938098)^{1, 2} Meyer P.... Klaes R. (2003)
86. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. (PubMed id 14581427)^{1, 4} Schwartz M.D....Lerman C. (2003)
87. Gynecologic surgeries and risk of ovarian cancer in women with BRCA1 and BRCA2 Ashkenazi founder mutations: an Israeli population-based case-control study. (PubMed id 12865453)^{1, 4} Rutter J.L....Hartge P. (2003)
88. Rad52 gene mutations in breast/ovarian cancer families and sporadic ovarian carcinoma patients. (PubMed id 12883740)^{1, 4} Tong D....Zeillinger R. (2003)
89. BRCA1 and BRCA2 sequence variants in Chinese breast cancer families. (PubMed id 12442274)^{1, 2} Zhi X.... Shi Y.-R. (2002)
90. Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype. (PubMed id 12404104)^{1, 4} Dagan E....Gershoni-Baruch R. (2002)
91. [Analysis of mutation sites of BRCA1 gene in Chinese patients with breast cancer] (PubMed id 12362311)^{1, 4} Ke Y....Lu D. (2002)
92. The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity. (PubMed id 11751867)^{1, 2} Sum E.Y....Visvader J.E. (2002)
93. [Frequency of the 185delAG mutation in the BRCA1 gene in Chilean healthy women with family history of breast cancer] (PubMed id 12491828)^{1, 4} Jara L....Ojeda J.M. (2002)
94. BRCA1 and BRCA2 mutation analysis of early-onset and familial breast cancer cases in Mexico. (PubMed id 12442275)^{1, 2} Ruiz-Flores P....Barrera-Saldana H.A. (2002)
95. Effect of germ-line genetic variation on breast cancer survival in a population-based study. (PubMed id 12036913)^{1, 4} Goode E.L....Pharoah P.P. (2002)
96. [Genetic test and prophylactic treatment in breast cancer families] (PubMed id 11977534)^{1, 4} Miyoshi Y. and Noguchi S. (2002)
97. [Investigation of mutations of BRCA1 and BRCA2 genes in 52 breast cancer patients] (PubMed id 12101561)^{1, 4} Tereshchenko I.V....Shagiakhmetova R.A. (2002)
98. Characterization of common BRCA1 and BRCA2 variants. (PubMed id 12215251)^{1, 2} Deffenbaugh A.M....Neuhausen S.L. (2002)
99. All in the family: evaluation of the process and content of sisters' communication about BRCA1 and BRCA2 genetic test results. (PubMed id 11807889)^{1, 4} Hughes C....Main D. (2002)
100. Phosphorylation of serine 1387 in BRCA1 is specifically required for the Atm-mediated S-phase checkpoint after ionizing irradiation. (PubMed id 12183412)^{1, 2} Xu B.... Kastan M.B. (2002)
101. SMC1 is a downstream effector in the ATM/NBS1 branch of the human S- phase checkpoint. (PubMed id 11877377)^{1, 2} Yazdi P.T.... Qin J. (2002)
102. A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire. (PubMed id 12433008)^{1, 4} Cella D....Lerman C. (2002)
103. A European case-only study on familial breast cancer. (PubMed id 12484126)^{1, 4} Berrino F....Bellati C. (2002)
104. NBS1 localizes to gamma-H2AX foci through interaction with the FHA/BRCT domain. (PubMed id 12419185)^{1, 2} Kobayashi J.... Komatsu K. (2002)
105. Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. (PubMed id 11573086)^{1, 2} Williams R.S....Glover J.N. (2001)
106. [Information to families with hereditary breast and ovarian cancer] (PubMed id 11826460)^{1, 4} Levin T....Moller P. (2001)
107. [Bilateral breast carcinoma and local recurrence: prevalence of BRCA-1 and BRCA-2 gene mutations in an unselected patient sample] (PubMed id 11505617)^{1, 4} Bremer M....Karstens J.H. (2001)
108. BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations. (PubMed id 11739404)^{1, 2} Ye Q.... Li R. (2001)
109. hCds1-mediated phosphorylation of BRCA1 regulates the DNA damage response. (PubMed id 10724175)^{1, 2} Lee J.S....Chung J.H. (2000)
110. An evaluation of needs of female BRCA1 and BRCA2 carriers undergoing genetic counselling. (PubMed id 11073541)^{1, 4} Metcalfe K.A....Narod S.A. (2000)
111. BASC, a super complex of BRCA1-associated proteins involved in the recognition and repair of aberrant DNA structures. (PubMed id 10783165)^{1, 2} Wang Y.... Qin J. (2000)
112. RING fingers mediate ubiquitin-conjugating enzyme (E2)-dependent ubiquitination. (PubMed id 10500182)^{1, 2} Lorick K.L....Weissman A.M. (1999)
113. Molecular characterization of germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in Taiwan. (PubMed id 10323242)^{1, 2} Li S.S.-L.... Tsai J.-H. (1999)
114. The contribution of germline BRCA1 and BRCA2 mutations to familial ovarian cancer: no evidence for other ovarian cancer-susceptibility genes. (PubMed id 10486320)^{1, 2} Gayther S.A....Ponder B.A.J. (1999)
115. Germline BRCA1 alterations in a population-based series of ovarian cancer cases. (PubMed id 10196379)^{1, 2} Janezic S.A.... Anton-Culver H. (1999)
116. BAP1: a novel ubiquitin hydrolase which binds to the BRCA1 RING finger and enhances BRCA1-mediated cell growth suppression. (PubMed id 9528852)^{1, 2} Jensen D.E.... Rauscher F.J. III (1998)
117. Characterization of a carboxy-terminal BRCA1 interacting protein. (PubMed id 9811458)^{1, 2} Wong A.K....Bartel P.L. (1998)
118. Constant denaturant gel electrophoresis (CDGE) in BRCA1 mutation screening. (PubMed id 9482581)^{1, 2} Andersen T.I.... Boerresen-Dale A.-L. (1998)
119. Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. (PubMed id 9010228)^{1, 2} Wilson C.A.... Calzone F.J. (1997)
120. Mutations and polymorphisms in the familial early-onset breast cancer (BRCA1) gene. (PubMed id 8807330)^{1, 2} Couch F.J. and Weber B.L. (1996)
121. BRCA1 mutations in primary breast and ovarian carcinomas. (PubMed id 7939630)^{1, 2} Futreal P.A.... Wiseman R. (1994)
122. Confirmation of BRCA1 by analysis of germline mutations linked to breast and ovarian cancer in ten families. (PubMed id 7894493)^{1, 2} Friedman L.S.... King M.-C. (1994)
123. Familial breast-ovarian cancer locus on chromosome 17q12-q23. (PubMed id 1676470)^{1, 3} Narod S.A....Lenoir G.M. (1991)
124. Extracellular matrix enhances heregulin-dependent BRCA1 phosphorylation and suppresses BRCA1 expression through its C terminus. (PubMed id 12509456)^{1, 9} Miralem T. and Avraham H.K. (2003)
125. BRCA1 and implications for response to chemotherapy in ovarian cancer. (PubMed id 19168207)^{1, 9} Quinn J.E....Harkin D.P. (2009)
126. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. (PubMed id 18208621)^{1, 9} Press J.Z....Huntsman D.G. (2008)
127. Inactivation of BRCA1 and BRCA2 in ovarian cancer. (PubMed id 12237285)^{1, 9} Hilton J.L....Buller R.E. (2002)
128. Transcriptional autoregulation by BRCA1. (PubMed id 20068145)^{1, 9} De Siervi A....Gardner K. (2010)
129. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. (PubMed id 19241424)^{1, 9} Hall M.J....Noll W.W. (2009)
130. [BRCA1 and BRCA2 mutations in families studied in the program of genetic counselling in cancer of the Valencian community (Spain)] (PubMed id 18279628)^{1, 9} Esteban Cardenosa E....Salas Trejo D. (2008)
131. Allelic imbalance in BRCA1 and BRCA2 gene expression is associated with an increased breast cancer risk. (PubMed id 18204050)^{1, 9} Chen X....Godwin A.K. (2008)
132. Mutations of the BRCA1 and BRCA2 genes in patients with bilateral breast cancer. (PubMed id 11556836)^{1, 9} Steinmann D....Dork T. (2001)
133. Phosphatidylinositol 3-kinase/Akt signaling enhances nuclear localization and transcriptional activity of BRCA1. (PubMed id 17428466)^{1, 9} Hinton C.V....Thompson M.E. (2007)
134. Regulation of BRCA1 phosphorylation by interaction with protein phosphatase 1alpha. (PubMed id 12438214)^{1, 9} Liu Y....Hsu L.C. (2002)
135. BRCA1 localization to the telomere and its loss from the telomere in response to DNA damage. (PubMed id 19797051)^{1, 9} Ballal R.D....Rosen E.M. (2009)
136. Tumor suppressor BRCA1 is expressed in prostate cancer and controls insulin-like growth factor I receptor (IGF-IR) gene transcription in an androgen receptor-dependent manner. (PubMed id 19223505)^{1, 9} Schayek H....Werner H. (2009)
137. Is there any relationship between BRCA1 gene mutation and pancreatic cancer development? (PubMed id 19140568)^{1, 9} Lawniczak M....StarzyA8ska T. (2008)
138. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation. (PubMed id 18445692)^{1, 9} Willems A.J....Thorne H.J. (2008)
139. Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country (Malaysia) with a relatively low incidence of breast cancer. (PubMed id 18627636)^{1, 9} Thirthagiri E....Teo S.H. (2008)
140. Involvement of a specificity proteins-binding element in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene. (PubMed id 18377656)^{1, 9} Hockings J.K....Romagnolo D.F. (2008)
141. Large genomic rearrangement in BRCA1 and BRCA2 and clinical characteristics of men with breast cancer in the United States. (PubMed id 17592676)^{1, 9} Tchou J....Nathanson K.L. (2007)
142. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. (PubMed id 17148771)^{1, 9} Risch H.A....Narod S.A. (2006)
143. Ubiquitination and proteasomal degradation of the BRCA1 tumor suppressor is regulated during cell cycle progression. (PubMed id 15166217)^{1, 9} Choudhury A.D....Baer R. (2004)
144. Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families. (PubMed id 11149425)^{1, 9} Ikeda N....Noguchi S. (2001)
145. Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families. (PubMed id 18546071)^{1, 9} Hansen T.O....Nielsen F.C. (2009)
146. Yeast screens identify the RNA polymerase II CTD and SPT5 as relevant targets of BRCA1 interaction. (PubMed id 18197258)^{1, 9} Bennett C.B....Marks J.R. (2008)
147. The interaction of PP1 with BRCA1 and analysis of their expression in breast tumors. (PubMed id 17511879)^{1, 9} Winter S.L....Andrulis I.L. (2007)
148. Novel germline mutations in breast cancer susceptibility genes BRCA1, BRCA2 and p53 gene in breast cancer patients from India. (PubMed id 15564800)^{1, 9} Hedau S....Das B.C. (2004)
149. Novel consensus DNA-binding sequence for BRCA1 protein complexes. (PubMed id 14502648)^{1, 9} Cable P.L....Afshari C.A. (2003)
150. Ataxia telangiectasia mutated (ATM) kinase and ATM and Rad3 related kinase mediate phosphorylation of Brca1 at distinct and overlapping sites. In vivo assessment using phospho-specific antibodies. (PubMed id 11278964)^{1, 9} Gatei M....Khanna K.K. (2001)
151. BRCA1 and BRCA2 germline mutation analysis among Indi an women from south India: identification of four novel mutations and high-freq uency occurrence of 185delAG mutation. (PubMed id 19805903)^{1, 9} Vaidyanathan K....Somasundaram K. (2009)
152. Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression. (PubMed id 19415121)^{1, 9} Rosell R....Taron M. (2009)
153. BRCA1 is regulated by Chk2 in response to spindle damage. (PubMed id 18804494)^{1, 9} Chabalier-Taste C....Larminat F. (2008)
154. BRCA1 promoter methylation in peripheral blood DNA of mutation negative familial breast cancer patients with a BRCA1 tumour phenotype. (PubMed id 18269736)^{1, 9} Snell C....Dobrovic A. (2008)
155. NFBD1/MDC1, 53BP1 and BRCA1 have both redundant and unique roles in the ATM pathway. (PubMed id 19001859)^{1, 9} Wilson K.A. and Stern D.F. (2008)
156. Contribution of BRCA1 and BRCA2 germline mutations to the incidence of early-onset breast cancer in Cyprus. (PubMed id 17250666)^{1, 9} Loizidou M....Kyriacou K. (2007)
157. Growth factor signaling pathways modulate BRCA1 repression of estrogen receptor-alpha activity. (PubMed id 17505062)^{1, 9} Ma Y....Rosen E.M. (2007)
158. BRCA1 DNA-binding activity is stimulated by BARD1. (PubMed id 16489000)^{1, 9} Simons A.M....Parvin J.D. (2006)
159. Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression. (PubMed id 16619214)^{1, 9} Chen X....Godwin A.K. (2006)
160. BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. (PubMed id 16644204)^{1, 9} Lalloo F....Evans D.G. (2006)
161. BRCA1 interaction with human papillomavirus oncoproteins. (PubMed id 15983032)^{1, 9} Zhang Y....Rosen E.M. (2005)
162. Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. (PubMed id 15728167)^{1, 9} Claus E.B....Carter D. (2005)
163. Germline BRCA1 promoter deletions in UK and Australian familial breast cancer patients: Identification of a novel deletion consistent with BRCA1:psiBRCA1 recombination. (PubMed id 11933198)^{1, 9} Brown M.A....Solomon E. (2002)
164. Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. (PubMed id 12400015)^{1, 9} Kawai H....Avraham H.K. (2002)
165. BRCA1 and BRCA2 heterozygosity and repair of X-ray-induced DNA damage. (PubMed id 12020440)^{1, 9} Nieuwenhuis B....Kampinga H.H. (2002)
166. Expression of BRCA1 and BRCA2 in different tumor cell lines with various growth status. (PubMed id 11983207)^{1, 9} Vissac C....Bernard-Gallon D.J. (2002)
167. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. (PubMed id 11710890)^{1, 9} King M.C....Fisher B. (2001)
168. Involvement of BRCA1 and BRCA2 in breast cancer in a western Finnish sub-population. (PubMed id 11180449)^{1, 9} Paakkonen K....Kere J. (2001)
169. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. (PubMed id 11244506)^{1, 9} Fan S....Rosen E.M. (2001)
170. Altered expression of BRCA1, BRCA2, and a newly identified BRCA2 exon 12 deletion variant in malignant human ovarian, prostate, and breast cancer cell lines. (PubMed id 10972993)^{1, 9} Rauh-Adelmann C....Ho S.M. (2000)
171. Mutations and alternative splicing of the BRCA1 gene in UK breast/ovarian cancer families. (PubMed id 9115959)^{1, 9} Xu C.F....Solomon E. (1997)
172. BRCA1 protein and nucleolin colocalize in breast carc inoma tissue and cancer cell lines. (PubMed id 20075200)^{1, 9} Tulchin N....Monteiro A.N. (2010)
173. The central region of BRCA1 binds preferentially to s upercoiled DNA. (PubMed id 19492866)^{1, 9} BrA!zda V....Arrowsmith C.H. (2009)
174. PALB2 functionally connects the breast cancer suscept ibility proteins BRCA1 and BRCA2. (PubMed id 19584259)^{1, 9} Zhang F....Andreassen P.R. (2009)
175. Immunolocalization of BRCA1 protein in tumor breast tissue: prescreening of BRCA1 mutation in Tunisian patients with hereditary breast cancer? (PubMed id 17921118)^{1, 9} Troudi W....Ben Ammar Elgaaied A. (2007)
176. High follicular phase luteinizing hormone levels in young healthy BRCA1 mutation carriers: implications for breast and ovarian cancer risk. (PubMed id 16084122)^{1, 9} Jernstrom H....Olsson H. (2005)
177. Association of BRCA1 with the inactive X chromosome and XIST RNA. (PubMed id 15065664)^{1, 9} Ganesan S....Livingston D.M. (2004)
178. Role of BRCA1 in heat shock response. (PubMed id 12527903)^{1, 9} Xian Ma Y....Rosen E.M. (2003)
179. Bovine BRCA1 shows classic responses to genotoxic stress but low in vitro transcriptional activation activity. (PubMed id 12955082)^{1, 9} Krum S.A....Lane T.F. (2003)
180. BRCA1 regulates GADD45 through its interactions with the OCT-1 and CAAT motifs. (PubMed id 11777930)^{1, 9} Fan W....Zhan Q. (2002)
181. BRCA1-induced apoptosis involves inactivation of ERK1/2 activities. (PubMed id 12082091)^{1, 9} Yan Y....Cowan K.H. (2002)
182. BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases. (PubMed id 9244350)^{1, 9} Wang H....Rao V.N. (1997)
183. Elevated expression of Ki-67 identifies aggressive pr ostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers. (PubMed id 20043088)^{1, 9} Mitra A.V.... C.S. (2010)
184. Methylation not a frequent 'second hit' in tumors with germline BRCA mutations. (PubMed id 19340607)^{1, 9} Dworkin A.M....Toland A.E. (2009)
185. Cisplatin-damaged BRCA1 exhibits altered thermostabil ity and transcriptional transactivation. (PubMed id 19270496)^{1, 9} Ratanaphan A....Prasertsan P. (2009)
186. Contralateral breast cancer risk in BRCA1 and BRCA2 m utation carriers. (PubMed id 19858402)^{1, 9} Graeser M.K....Schmutzler R.K. (2009)
187. Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1. (PubMed id 18176857)^{1, 9} Miramar M.D....Garcia de Jalon A. (2008)
188. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Cuba. (PubMed id 18286383)^{1, 9} Rodriguez R.C....Narod S.A. (2008)
189. Molecular and in silico analysis of BRCA1 and BRCA2 variants. (PubMed id 18694767)^{1, 9} Tommasi S....Paradiso A. (2008)
190. BRCA1 germline mutations and tumor characteristics in Chinese women with familial or early-onset breast cancer. (PubMed id 18512148)^{1, 9} Chen W....Xie Y. (2008)
191. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain. (PubMed id 18060494)^{1, 9} Esteban Cardenosa E....Martinez de Duenas E. (2008)
192. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. (PubMed id 17063270)^{1, 9} Gomes M.C....Narod S.A. (2007)
193. Common variation in the BRCA1 gene and prostate cancer risk. (PubMed id 17585057)^{1, 9} Douglas J.A....Cooney K.A. (2007)
194. Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. (PubMed id 17196508)^{1, 9} McLaughlin J.R....Narod S.A. (2007)
195. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India. (PubMed id 17018160)^{1, 9} Saxena S....Szabo C.I. (2006)
196. [BRCA1 and BRCA2 gene mutations of familial breast cancer from Shanghai in China] (PubMed id 16456781)^{1, 9} Song C.G....Shao Z.M. (2006)
197. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations. (PubMed id 16261400)^{1, 9} Gallardo M....Carvallo P. (2006)
198. BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families. (PubMed id 16826315)^{1, 9} Peixoto A....Teixeira M.R. (2006)
199. Analysis of BRCA1 and BRCA2 mutations in Brazilian breast cancer patients with positive family history. (PubMed id 16389418)^{1, 9} Dufloth R.M....Schmitt F. (2005)
200. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. (PubMed id 15863145)^{1, 9} Casey M.J....Lynch H.T. (2005)
201. BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy. (PubMed id 16026807)^{1, 9} Tommasi S....Paradiso A. (2005)
202. BRCA1 mutations in a population-based study of breast cancer in Stockholm County. (PubMed id 15345109)^{1, 9} Margolin S....Lindblom A. (2004)
203. Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma: 10-year follow up data. (PubMed id 12548593)^{1, 9} Goffin J.R....Foulkes W.D. (2003)
204. Functional and physical interactions between BRCA1 and p53 in transcriptional regulation of the IGF-IR gene. (PubMed id 14710355)^{1, 9} Abramovitch S. and Werner H. (2003)
205. siRNA depletion of BRCA1, but not BRCA2, causes increased genome instability in Fanconi anemia cells. (PubMed id 12967657)^{1, 9} Bruun D....Moses R. (2003)
206. Similar contributions of BRCA1 and BRCA2 germline mutations to early-onset breast cancer in Germany. (PubMed id 12774040)^{1, 9} Hamann U....Sinn H.P. (2003)
207. BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis. (PubMed id 14559807)^{1, 9} Quinn J.E....Harkin D.P. (2003)
208. Correlation between BRCA1 expression and apoptosis-related biological parameters in sporadic breast carcinomas. (PubMed id 12552965)^{1, 9} Yang Q....Kakudo K. (2002)
209. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. (PubMed id 12464649)^{1, 9} Narod S.A....Brunet J.S. (2002)
210. BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. (PubMed id 11844822)^{1, 9} Shih H.A....Weber B.L. (2002)
211. The p53 mutational spectrum associated with BRCA1 mutant ovarian cancer. (PubMed id 11309330)^{4, 9} Buller R.E....Kirby P.A. (2001)
212. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. (PubMed id 11698567)^{1, 9} Hartmann L.C....Jenkins R.B. (2001)
213. Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group. (PubMed id 11044354)^{1, 9} (2000)
214. Cell cycle-dependent colocalization of BARD1 and BRCA1 proteins in discrete nuclear domains. (PubMed id 9342365)^{1, 9} Jin Y....Baer R. (1997)
215. Targeting the FANCJ-BRCA1 interaction promotes a swit ch from recombination to poleta-dependent bypass. (PubMed id 20173781)^{1, 9} Xie J....Cantor S.B. (2010)
216. BRCA1 promoter methylation associated with poor survi val in Chinese patients with sporadic breast cancer. (PubMed id 19522853)^{1, 9} Chen Y....Deng D. (2009)
217. Associations of high-grade prostate cancer with BRCA1 and BRCA2 founder mutations. (PubMed id 19188187)^{1, 9} Agalliu I....Burk R.D. (2009)
218. Genetic variation in insulin-like growth factor signa ling genes and breast cancer risk among BRCA1 and BRCA2 carriers. (PubMed id 19843326)^{1, 9} Neuhausen S.L....Gillen D.L. (2009)
219. A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMO-dependent/independent activities of Ubc9 on E2-induced ERalpha activation/repression and degradation in breast cancer cells. (PubMed id 19287951)^{1, 9} Xu J....Rao V.N. (2009)
220. Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair. (PubMed id 18171670)^{1, 9} Chen L....Wu X. (2008)
221. Nuclear export of BRCA1 occurs during early S phase and is calcium-dependent. (PubMed id 18296025)^{1, 9} Glover-Collins K. and Thompson M.E. (2008)
222. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1. (PubMed id 18957670)^{1, 9} Lose F.... . (2008)
223. Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. (PubMed id 18355772)^{1, 9} Antoniou A.C....Easton D.F. (2008)
224. The effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other deleterious CHEK2 or BRCA1 mutations. (PubMed id 18930998)^{1, 9} Cybulski C....Lubinski J. (2008)
225. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. (PubMed id 18812548)^{1, 9} Eisen A....Narod S.A. (2008)
226. The CHEK2 1100delC mutation is not present in Korean patients with breast cancer cases tested for BRCA1 and BRCA2 mutation. (PubMed id 18175216)^{1, 9} Choi D.H....Haffty B.G. (2008)
227. Variation of breast cancer risk among BRCA1/2 carriers. (PubMed id 18182601)^{1, 9} Begg C.B....Bernstein J.L. (2008)
228. Concerted transcriptional regulation by BRCA1 and COBRA1 in breast cancer cells. (PubMed id 18071589)^{1, 9} Aiyar S.E....Li R. (2007)
229. Brca1 heterozygous mice have shortened life span and are prone to ovarian tumorigenesis with haploinsufficiency upon ionizing irradiation. (PubMed id 17420720)^{1, 9} Jeng Y.M....Lee W.H. (2007)
230. Prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer. (PubMed id 17520345)^{1, 9} Elsakov P....Ostapenko V. (2007)
231. Role of single nucleotide polymorphisms and haplotypes in BRCA1 in breast cancer: Czech case-control study. (PubMed id 17039264)^{1, 9} Soucek P....Novotny J. (2007)
232. BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry. (PubMed id 15872055)^{1, 9} Al-Mulla F....Anim J.T. (2005)
233. Truncating BRCA1 mutations are uncommon in a cohort of hereditary prostate cancer families with evidence of linkage to 17q markers. (PubMed id 15447980)^{1, 9} Zuhlke K.A....Cooney K.A. (2004)
234. Nuclear-cytoplasmic shuttling of BARD1 contributes to its proapoptotic activity and is regulated by dimerization with BRCA1. (PubMed id 14647430)^{1, 9} Rodriguez J.A....Henderson B.R. (2004)
235. Contribution of BRCA1 and BRCA2 to familial ovarian cancer: a gynecologic oncology group study. (PubMed id 11972384)^{1, 9} Reedy M....Smith S.A. (2002)
236. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer. (PubMed id 11504767)^{1, 9} Loman N....Borg A. (2001)
237. BRCA1 germline mutations and polymorphisms in a clinic-based series of ovarian cancer cases: a Gynecologic Oncology Group study. (PubMed id 11733976)^{1, 9} Smith S.A....Gallion H.H. (2001)
238. Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. (PubMed id 11410514)^{1, 9} Chang J....Ragu G.C. (2001)
239. Novel germline BRCA1 and BRCA2 mutations in breast and breast/ovarian cancer families from the Czech Republic. (PubMed id 11748848)^{1, 9} Machackova E....Foretova L. (2001)
240. Mapping the functional domains of BRCA1. Interaction of the ring finger domains of BRCA1 and BARD1. (PubMed id 10026184)^{1, 9} Meza J.E.... Klevit R.E. (1999)
241. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter. (PubMed id 9926942)^{1, 9} Chai Y.L....Rao V.N. (1999)
242. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. (PubMed id 9102202)^{4, 9} Tirkkonen M....Kallioniemi O.P. (1997)
243. Population-based study of the risk of second primary contralateral breast cancer associated with carrying a mutation in BRCA1 or BRC A2. (PubMed id 20368571)^{1, 9} Malone K.E....Bernstein J.L. (2010)
244. Immunohistochemical expression of BRCA1 and lethal pr ostate cancer. (PubMed id 20388772)^{1, 9} Fiorentino M....Mucci L. (2010)
245. Analysis of BRCA1 and BRCA2 mutations in southern Ira nian Breast cancer patients. (PubMed id 19877752)^{1, 9} Fattahi M.J....Ghaderi A. (2009)
246. The Leu33Pro polymorphism in the ITGB3 gene does not modify BRCA1/2-associated breast or ovarian cancer risks: results from a multic enter study among 15,542 BRCA1 and BRCA2 mutation carriers. (PubMed id 19876733)^{1, 9} Jakubowska A....Lubinski J. (2009)
247. Common variants in LSP1, 2q35 and 8q24 and breast can cer risk for BRCA1 and BRCA2 mutation carriers. (PubMed id 19656774)^{1, 9} Antoniou A.C....Chen X. (2009)
248. Selenium supplementation reduced oxidative DNA damage in adnexectomized BRCA1 mutations carriers. (PubMed id 19843683)^{1, 9} Dziaman T....Olinski R. (2009)
249. Missense polymorphisms in BRCA1 and BRCA2 and risk of breast and ovarian cancer. (PubMed id 19661094)^{1, 9} Dombernowsky S.L....Nordestgaard B.G. (2009)
250. [The prevalence of BRCA1 mutations among families at high-risk of breast and ovarian cancer in province of Malopolska between 2004-2 009] (PubMed id 20514903)^{1, 9} Blecharz P....UrbaA8ski K. (2009)
251. The contribution of BRCA1 and BRCA2 to ovarian cancer. (PubMed id 19383375)^{1, 9} Ramus S.J. and Gayther S.A. (2009)
252. Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families. (PubMed id 18501021)^{1, 9} PylkAos K....Winqvist R. (2008)
253. AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51. (PubMed id 19010915)^{1, 9} Plo I....Lopez B.S. (2008)
254. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark. (PubMed id 18559594)^{1, 9} Soegaard M....Ramus S.J. (2008)
255. Promotion of BRCA1-associated triple-negative breast cancer by ovarian hormones. (PubMed id 18197009)^{1, 9} Lee E.Y. (2008)
256. BRCA1 mutations in Algerian breast cancer patients: high frequency in young, sporadic cases. (PubMed id 18645608)^{1, 9} Uhrhammer N....Bignon Y.J. (2008)
257. The spectrum and incidence of BRCA1 pathogenic mutations in Slovak breast/ovarian cancer families. (PubMed id 17319787)^{1, 9} Konecny M....Kausitz J. (2007)
258. [BRCA1 germ line mutations in Chinese early-onset breast cancer patients] (PubMed id 17922413)^{1, 9} Li W.F....Shao Z.M. (2007)
259. Germline BRCA1 mutation and survival analysis in familial breast cancer patients in Kerala; South India. (PubMed id 17987791)^{1, 9} Vinodkumar B....Ankathil R. (2007)
260. A review of histopathological subtypes of ovarian cancer in BRCA-related French Canadian cancer families. (PubMed id 17636423)^{1, 9} Tonin P.N....Provencher D.M. (2007)
261. BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials. (PubMed id 18094417)^{1, 9} Tilanus-Linthorst M.M....Gilbert F.J. (2007)
262. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers. (PubMed id 17301259)^{1, 9} Jakubowska A....Hamann U. (2007)
263. Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families. (PubMed id 17333342)^{1, 9} Buffone A....Giannini G. (2007)
264. The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. (PubMed id 16109739)^{1, 9} Ma Y....Rosen E.M. (2006)
265. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. (PubMed id 16537453)^{1, 9} Simchoni S....Levy-Lahad E. (2006)
266. Spontaneous and therapeutic abortions and the risk of breast cancer among BRCA mutation carriers. (PubMed id 16563180)^{1, 9} Friedman E....Narod S.A. (2006)
267. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. (PubMed id 16284991)^{1, 9} Pal T....Sutphen R. (2005)
268. An estrogen receptor-alpha/p300 complex activates the BRCA-1 promoter at an AP-1 site that binds Jun/Fos transcription factors: repressive effects of p53 on BRCA-1 transcription. (PubMed id 16229810)^{1, 9} Jeffy B.D....Romagnolo D.F. (2005)
269. Identification of germline BRCA1 and BRCA2 genetic alterations in Greek breast cancer moderate-risk and low-risk individuals--correlation with clinicopathological data. (PubMed id 15733268)^{1, 9} Kataki A....Konstadoulakis M. (2005)
270. 53BP1 is a positive regulator of the BRCA1 promoter. (PubMed id 15970701)^{1, 9} Rauch T....Xu X. (2005)
271. In vitro platination of human breast cancer suppressor gene1 (BRCA1) by the anticancer drug carboplatin. (PubMed id 16099593)^{1, 9} Ratanaphan A....Mahasawat P. (2005)
272. Cyclin D1 antagonizes BRCA1 repression of estrogen receptor alpha activity. (PubMed id 16061635)^{1, 9} Wang C....Pestell R.G. (2005)
273. BARD1 regulates BRCA1 apoptotic function by a mechanism involving nuclear retention. (PubMed id 15265711)^{1, 9} Fabbro M....Henderson B.R. (2004)
274. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. (PubMed id 15265971)^{1, 9} Jernstrom H....Narod S.A. (2004)
275. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. (PubMed id 15477862)^{1, 9} Bjorge T....Dorum A. (2004)
276. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations. (PubMed id 15545966)^{1, 9} Whittemore A.S....Piver M.S. (2004)
277. Both DNA topoisomerase II-binding protein 1 and BRCA1 regulate the G2-M cell cycle checkpoint. (PubMed id 12810625)^{1, 9} Yamane K....Kinsella T.J. (2003)
278. BRCA1 augments transcription by the NF-kappaB transcription factor by binding to the Rel domain of the p65/RelA subunit. (PubMed id 12700228)^{1, 9} Benezra M....Licht J.D. (2003)
279. Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations. (PubMed id 11870509)^{1, 9} Duffy S.W. and Nixon R.M. (2002)
280. Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. (PubMed id 12237282)^{1, 9} Brose M.S....Weber B.L. (2002)
281. CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q. (PubMed id 12019214)^{1, 9} Nathanson K.L....Weber B.L. (2002)
282. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. (PubMed id 11474660)^{1, 9} Modan B....Piura B. (2001)
283. Germline BRCA1 mutations in Iranian women with breast cancer. (PubMed id 11248423)^{1, 9} Ghaderi A....Kimura H. (2001)
284. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. (PubMed id 11130383)^{1, 9} Narod S.A....Lynch H. (2000)
285. Conservation of function and primary structure in the BRCA1-associated RING domain (BARD1) protein. (PubMed id 9798686)^{1, 9} Ayi T.C....Baer R. (1998)
286. Somatic mutations in the BRCA1 gene in sporadic ovarian tumours. (PubMed id 7795652)^{1, 9} Merajver S.D....Frank T.S. (1995)
287. Negative feedback loop of BRCA1-BARD1 ubiquitin ligas e on estrogen receptor alpha stability and activity antagonized by cancer-assoc iated isoform of BARD1. (PubMed id 20060929)^{1, 9} Dizin E. and Irminger-Finger I. (2010)
288. Use of DNA-damaging agents and RNA pooling to assess expression profiles associated with BRCA1 and BRCA2 mutation status in familial breast cancer patients. (PubMed id 20174566)^{1, 9} Walker L.C....Spurdle A.B. (2010)
289. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. (PubMed id 19648928)^{1, 9} Lim E....Lindeman G.J. (2009)
290. Association of loss of BRCA1 expression with centrosome aberration in human breast cancer. (PubMed id 18813953)^{1, 9} Shimomura A....Noguchi S. (2009)
291. Age at onset of bilateral breast cancer, the presence of hereditary BRCA1, BRCA2, CHEK2 gene mutations and positive family history of cancer. (PubMed id 19372713)^{1, 9} Skasko E....PieA8kowski T. (2009)
292. Aneuploidy is associated with TP53 expression but not with BRCA1 or TERT expression in sporadic colorectal cancer. (PubMed id 20032382)^{1, 9} SchjA...De Angelis P.M. (2009)
293. Clinical characteristics of laryngeal cancer in BRCA- 1 mutation carriers. (PubMed id 19596949)^{1, 9} Jaworowska E....LubiA8ski J. (2009)
294. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. (PubMed id 18451254)^{1, 9} Milne R.L....Benitez J. (2008)
295. Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas. (PubMed id 18717684)^{1, 9} Becker K....Ballhausen W.G. (2008)
296. Haplotype analysis of TP53 polymorphisms, Arg72Pro and Ins16, in BRCA1 and BRCA2 mutation carriers of French Canadian descent. (PubMed id 18402691)^{1, 9} Cavallone L....Tonin P.N. (2008)
297. Germline TP53 mutations in BRCA1 and BRCA2 mutation-negative French Canadian breast cancer families. (PubMed id 17541742)^{1, 9} Arcand S.L....Tonin P.N. (2008)
298. Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations. (PubMed id 18855126)^{1, 9} Kim D.H....Beattie M.S. (2008)
299. BRCA1 mutations and prostate cancer in Poland. (PubMed id 18090912)^{1, 9} Cybulski C....Lubinski J. (2008)
300. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. (PubMed id 17661168)^{1, 9} Falchetti M....Ottini L. (2008)
301. Tumor BRCA1, RRM1 and RRM2 mRNA expression levels and clinical response to first-line gemcitabine plus docetaxel in non-small-cell lung cancer patients. (PubMed id 19002265)^{1, 9} Boukovinas I....Souglakos J. (2008)
302. BRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model. (PubMed id 18695886)^{1, 9} Yu X....Tang Y. (2008)
303. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. (PubMed id 18779615)^{1, 9} Atchley D.P....Arun B.K. (2008)
304. Common variants in the ATM, BRCA1, BRCA2, CHEK2 and TP53 cancer susceptibility genes are unlikely to increase breast cancer risk. (PubMed id 17428325)^{1, 9} Baynes C....Dunning A.M. (2007)
305. Counting potentially functional variants in BRCA1, BRCA2 and ATM predicts breast cancer susceptibility. (PubMed id 17341484)^{1, 9} Johnson N....Peto J. (2007)
306. BRCA1 and TP53 mutation spectrum of breast carcinoma in an ethnic population of Kashmir, an emerging high-risk area. (PubMed id 16996204)^{1, 9} Eachkoti R....Siddiqi M.A. (2007)
307. Risks of cancer due to a single BRCA1 mutation in an extended Utah kindred. (PubMed id 17051349)^{1, 9} Vogl F.D....Goldgar D.E. (2007)
308. Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients. (PubMed id 17599361)^{1, 9} Mirza S....Ralhan R. (2007)
309. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma. (PubMed id 17624602)^{1, 9} Monnerat C....Bressac-de Paillerets B. (2007)
310. A role of estrogen/ERalpha signaling in BRCA1-associated tissue-specific tumor formation. (PubMed id 17496925)^{1, 9} Li W....Deng C.X. (2007)
311. Somatic loss of BRCA1 and p53 in mice induces mammary tumors with features of human BRCA1-mutated basal-like breast cancer. (PubMed id 17626182)^{1, 9} Liu X....Jonkers J. (2007)
312. Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines. (PubMed id 17321670)^{1, 9} Burkitt K. and Ljungman M. (2007)
313. Elevated insulin-like growth factor-I receptor (IGF-IR) levels in primary breast tumors associated with BRCA1 mutations. (PubMed id 17766039)^{1, 9} Maor S....Werner H. (2007)
314. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. (PubMed id 18042939)^{1, 9} Tai Y.C....Chen S. (2007)
315. Genetic analysis of BRCA1 ubiquitin ligase activity and its relationship to breast cancer susceptibility. (PubMed id 16403807)^{1, 9} Morris J.R....Solomon E. (2006)
316. Basal repression of BRCA1 by multiple E2Fs and pocket proteins at adjacent E2F sites. (PubMed id 17106239)^{1, 9} Bindra R.S. and Glazer P.M. (2006)
317. Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer. (PubMed id 16533773)^{1, 9} Grabsch H....Mueller W. (2006)
318. Mutational analysis of the estrogen receptor-alpha gene in familial ovarian cancer. (PubMed id 16176503)^{1, 9} Wu H.J....Tanaka K. (2005)
319. Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic. (PubMed id 15880530)^{1, 9} Horsburgh S....Trachtenberg J. (2005)
320. Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2. (PubMed id 15665273)^{1, 9} Hayami R....Ohta T. (2005)
321. Novel somatic mutations in the BRCA1 gene in sporadic breast tumors. (PubMed id 15712267)^{1, 9} Janatova M....Pohlreich P. (2005)
322. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. (PubMed id 14668548)^{1, 9} Carcangiu M.L....Pasini B. (2004)
323. Down-regulation of BRCA1 in chronic pancreatitis and sporadic pancreatic adenocarcinoma. (PubMed id 15173085)^{1, 9} Beger C....Beger H.G. (2004)
324. BRCA1 testing in breast and/or ovarian cancer families from northeastern France identifies two common mutations with a founder effect. (PubMed id 15131401)^{1, 9} Muller D....Fricker J.P. (2004)
325. Nucleophosmin/B23 is a candidate substrate for the BRCA1-BARD1 ubiquitin ligase. (PubMed id 15184379)^{1, 9} Sato K....Ohta T. (2004)
326. Functional dissection of transcription factor ZBRK1 reveals zinc fingers with dual roles in DNA-binding and BRCA1-dependent transcriptional repression. (PubMed id 14660588)^{1, 9} Tan W....Boyer T.G. (2004)
327. Comparison of BRCT domains of BRCA1 and 53BP1: a biophysical analysis. (PubMed id 14978302)^{1, 9} Ekblad C.M....Itzhaki L.S. (2004)
328. BRCA mutations and risk of prostate cancer in Ashkenazi Jews. (PubMed id 15131025)^{1, 9} Kirchhoff T....Offit K. (2004)
329. Vascular endothelial growth factor (VEGF) levels and mutation of the BRCA1 gene in breast cancer patients. (PubMed id 15609132)^{1, 9} Tarnowski B....Rzepka-Gorska I. (2004)
330. Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control. (PubMed id 12611903)^{1, 9} Lou Z.... Chen J. (2003)
331. Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein. (PubMed id 12431996)^{1, 9} Xia Y....Hunter T. (2003)
332. TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms. (PubMed id 14673037)^{1, 9} Nichols K.E....Diller L. (2003)
333. Hereditary ovarian cancer in Poland. (PubMed id 12918074)^{1, 9} Menkiszak J....Lubinski J. (2003)
334. Mutation analysis of BrCA1, BrCA2, and p53 versus soluble HLA class I and class II in a case of familial endometriosis. (PubMed id 12568865)^{1, 9} Goumenou A.G....Koutsilieris M. (2003)
335. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. (PubMed id 12473589)^{1, 9} Satagopan J.M....Offit K. (2002)
336. Loss of BRCA1 expression in sporadic male breast carcinoma. (PubMed id 11859870)^{1, 9} Sun X....Badve S. (2002)
337. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families. (PubMed id 12402332)^{1, 9} Phelan C.M....Narod S.A. (2002)
338. Analysis of BRCA1, TP53, and TSG101 germline mutations in German breast and/or ovarian cancer families. (PubMed id 12505256)^{1, 9} Balz V....Bojar H. (2002)
339. Constitutive association of BRCA1 and c-Abl and its ATM-dependent disruption after irradiation. (PubMed id 12024016)^{1, 9} Foray N....Jeggo P. (2002)
340. Activation of the aromatic hydrocarbon receptor pathway is not sufficient for transcriptional repression of BRCA-1: requirements for metabolism of benzo[a]pyrene to 7r,8t-dihydroxy-9t,10-epoxy-7,8,9,10-tetrahydrobenzo[a]pyrene. (PubMed id 11782367)^{1, 9} Jeffy B.D....Romagnolo D.F. (2002)
341. Contribution of BRCA1 and BRCA2 mutations to breast and ovarian cancer in Pakistan. (PubMed id 12181777)^{1, 9} Liede A....Narod S.A. (2002)
342. Expression profiles of BRCA1 splice variants in asynchronous and in G1/S synchronized tumor cell lines. (PubMed id 11162473)^{1, 9} Orban T.I. and Olah E. (2001)
343. The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by a breast cancer-derived mutation. (PubMed id 11278247)^{1, 9} Hashizume R....Ohta T. (2001)
344. BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor. (PubMed id 11493692)^{1, 9} Zheng L....Boyer T.G. (2001)
345. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. (PubMed id 11377596)^{1, 9} Narod S.A....Neuhausen S.L. (2001)
346. Sequence-specific transcriptional corepressor function for BRCA1 through a novel zinc finger protein, ZBRK1. (PubMed id 11090615)^{1, 9} Zheng L....Lee H.W. (2000)
347. Increase of androgen-induced cell death and androgen receptor transactivation by BRCA1 in prostate cancer cells. (PubMed id 11016951)^{1, 9} Yeh S....Chang C. (2000)
348. BRCA1 inhibition of estrogen receptor signaling in transfected cells. (PubMed id 10334989)^{1, 9} Fan S....Rosen E.M. (1999)
349. Association of BRCA1 with Rad51 in mitotic and meiotic cells. (PubMed id 9008167)^{1, 9} Scully R....Livingston D.M. (1997)
350. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. (PubMed id 20216074)^{1, 9} Petrucelli N....Feldman G.L. (2010)
351. BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia. (PubMed id 20380699)^{1, 9} Tamboom K....Veidebaum T. (2010)
352. Excretion of estrogens, catecholestrogens and phytoes trogens in carriers of BRCA1 gene mutations: effects of metformin. (PubMed id 20429624)^{1, 9} Berstein L.M....Adlercreutz H. (2010)
353. Mammalian SUMO E3-ligases PIAS1 and PIAS4 promote res ponses to DNA double-strand breaks. (PubMed id 20016603)^{1, 9} Galanty Y....Jackson S.P. (2009)
354. BRCA1 expression and molecular alterations in familial breast cancer. (PubMed id 19012246)^{1, 9} Mangia A....Paradiso A. (2009)
355. Promoter methylation patterns of ATM, ATR, BRCA1, BRC A2 and P53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation car riers. (PubMed id 18642075)^{1, 9} Kontorovich T....Friedman E. (2009)
356. [Analysis of polymorphisms in genes of insulin recept or substrate-1 and enzymes involved in estrogen biosynthesis and metabolism amo ng breast cancer patients with BRCA1 mutations] (PubMed id 19514368)^{1, 9} BershteA-n L.M....Imianitov E.N. (2009)
357. Prospective study of breast MRI in BRCA1 and BRCA2 mu tation carriers: effect of mutation status on cancer incidence. (PubMed id 19609668)^{1, 9} Shah P....Domchek S.M. (2009)
358. Polymorphisms in BRCA1, BRCA1-interacting genes and s usceptibility of breast cancer in Chinese women. (PubMed id 19484476)^{1, 9} Huo X....Tang J. (2009)
359. A role for BRCA1 in uterine leiomyosarcoma. (PubMed id 19843854)^{1, 9} Xing D....Orsulic S. (2009)
360. Expression profile of BRCA1 and BRCA2 genes in premen opausal Mexican women with breast cancer: clinical and immunohistochemical corr elates. (PubMed id 19012002)^{1, 9} Loredo-Pozos G....Ramos-MA!rquez M.E. (2009)
361. Resveratrol induces senescence-like growth inhibition of U-2 OS cells associated with the instability of telomeric DNA and upregulat ion of BRCA1. (PubMed id 19559722)^{1, 9} Rusin M....Butkiewicz D. (2009)
362. High frequency of BRCA1, but not CHEK2 or NBS1 (NBN), founder mutations in Russian ovarian cancer patients. (PubMed id 19338682)^{1, 9} Suspitsin E.N....Imyanitov E.N. (2009)
363. BRCA1 down-regulates cellular levels of reactive oxygen species. (PubMed id 19364506)^{1, 9} Saha T....Rosen E.M. (2009)
364. The DNA repair proteins BRCA1 and ERCC1 as predictive markers in sporadic ovarian cancer. (PubMed id 19035454)^{1, 9} Weberpals J....Dimitroulakos J. (2009)
365. The Fanconi anemia family of genes and its correlatio n with breast cancer susceptibility and breast cancer features. (PubMed id 19536649)^{1, 9} Barroso E....Ribas G. (2009)
366. Distinct roles of BARD1 isoforms in mitosis: full-length BARD1 mediates Aurora B degradation, cancer-associated BARD1beta scaffolds Aurora B and BRCA2. (PubMed id 19176389)^{1, 9} Ryser S....Irminger-Finger I. (2009)
367. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions. (PubMed id 18997820)^{1, 9} Wen J....Shupnik M.A. (2009)
368. Dynamic interactions between the promoter and terminator regions of the mammalian BRCA1 gene. (PubMed id 18375767)^{1, 9} Tan-Wong S.M....Brown M.A. (2008)
369. Expression of BRCA1 protein in breast cancer and its prognostic significance. (PubMed id 18400253)^{1, 9} Rakha E.A....Ellis I.O. (2008)
370. [Influence of mifepristone on DNA repair genes and cisplatin sensitivity in human ovarian cancer drug-resistance cells] (PubMed id 18683754)^{1, 9} Liu G.Y....Qi J. (2008)
371. Dinucleotide repeat polymorphisms of RAD51, BRCA1, BRCA2 gene regions in breast cancer. (PubMed id 18429825)^{1, 9} Nowacka-Zawisza M....Krajewska W.M. (2008)
372. Expression of estrogen receptor beta in the breast carcinoma of BRCA1 mutation carriers. (PubMed id 18405391)^{1, 9} Litwiniuk M.M....Breborowicz J. (2008)
373. Predominant Ashkenazi BRCA1/2 mutations in families with pancreatic cancer. (PubMed id 18439109)^{1, 9} Dagan E. (2008)
374. [Evaluation of stomatognathic system in BRCA1 gene mutation carriers before and after prophylactic adnexectomy--part II: evaluation of stomatognathic system in BRCA1 gene mutation carriers after prophylactic adnexectomy] (PubMed id 19374245)^{1, 9} ChruA9ciel-Nogalska M. (2008)
375. Rapid progression of prostate cancer in men with a BRCA2 mutation. (PubMed id 18577985)^{1, 9} Narod S.A....Bellati C. (2008)
376. Re-engineering a split-GFP reassembly screen to examine RING-domain interactions between BARD1 and BRCA1 mutants observed in cancer patients. (PubMed id 18493658)^{1, 9} Sarkar M. and Magliery T.J. (2008)
377. BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. (PubMed id 18094425)^{1, 9} Quinn J.E....Harkin D.P. (2007)
378. RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. (PubMed id 17999359)^{1, 9} Antoniou A.C....Chenevix-Trench G. (2007)
379. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. (PubMed id 17308087)^{1, 9} Carvalho M.A....Monteiro A.N. (2007)
380. RAD51 up-regulation bypasses BRCA1 function and is a common feature of BRCA1-deficient breast tumors. (PubMed id 17942895)^{1, 9} Martin R.W....Bishop D.K. (2007)
381. X inactive-specific transcript RNA coating and genetic instability of the X chromosome in BRCA1 breast tumors. (PubMed id 17545591)^{1, 9} Vincent-Salomon A....Heard E. (2007)
382. Elevated levels of somatic mutation in a manifesting BRCA1 mutation carrier. (PubMed id 18158561)^{1, 9} Grant S.G....Latimer J.J. (2007)
383. The FANCJ/MutLalpha interaction is required for correction of the cross-link response in FA-J cells. (PubMed id 17581638)^{1, 9} Peng M....Cantor S.B. (2007)
384. Regulation of the BRCA1 promoter in ovarian surface epithelial cells and ovarian carcinoma cells. (PubMed id 17434164)^{1, 9} Graves M.L....Roskelley C.D. (2007)
385. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. (PubMed id 16331614)^{1, 9} Gronwald J....Narod S.A. (2006)
386. CAG repeat length in exon 1 of the androgen receptor gene is related to age of diagnosis but not germ line BRCA1 mutation status in ovarian cancer. (PubMed id 16515589)^{1, 9} Kim S.C....Buller R.E. (2006)
387. Medullary carcinoma of breast with a novel germline mutation 1123T >G in exon 11 of BRCA1. (PubMed id 16945238)^{1, 9} Moattar T....Pervez S. (2006)
388. Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients. (PubMed id 16998791)^{1, 9} Rashid M.U....Hamann U. (2006)
389. Premature menopause in patients with BRCA1 gene mutation. (PubMed id 16773440)^{1, 9} Rzepka-Gorska I....Tol/oczko-Grabarek A. (2006)
390. [Analysis of loss of heterozygosity and microsatellite instability RAD52, RAD54 and RAD54B gene and BRCA1 gene mutation in breast cancer] (PubMed id 17405295)^{1, 9} Romanowicz-Makowska H. and Smolarz B. (2006)
391. TP53 mutations in ovarian carcinomas from sporadic ca ses and carriers of two distinct BRCA1 founder mutations; relation to age at di agnosis and survival. (PubMed id 16229746)^{1, 9} Kringen P....Dorum A. (2005)
392. Phosphorylated BRCA1 is predominantly located in the nucleus and mitochondria. (PubMed id 15591126)^{1, 9} Coene E.D....Vaux D.J. (2005)
393. Prognostic impact of BRCA1 pathogenic and BRCA1/BRCA2 unclassified variant mutations in patients with ovarian carcinoma. (PubMed id 16047333)^{1, 9} Majdak E.J....De Bock G.H. (2005)
394. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations. (PubMed id 15734957)^{1, 9} Milne R.L....Whittemore A.S. (2005)
395. Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. (PubMed id 16170371)^{1, 9} Hu Y....Li R. (2005)
396. BRCA1 in hormonal carcinogenesis: basic and clinical research. (PubMed id 16172191)^{1, 9} Rosen E.M....Isaacs C. (2005)
397. BRIT1/MCPH1 is a DNA damage responsive protein that regulates the Brca1-Chk1 pathway, implicating checkpoint dysfunction in microcephaly. (PubMed id 16217032)^{1, 9} Lin S.Y....Elledge S.J. (2005)
398. ATR and GADD45alpha mediate HIV-1 Vpr-induced apoptosis. (PubMed id 15650754)^{1, 9} Andersen J.L....Planelles V. (2005)
399. BRCA1 gene expression in breast cancer in Kuwait: correlation with prognostic parameters. (PubMed id 15785095)^{1, 9} Amirrad M....Anim J.T. (2005)
400. BRCA1 and pancreatic cancer: pedigree findings and their causal relationships. (PubMed id 15796958)^{1, 9} Lynch H.T....Brand R.E. (2005)
401. Germ-line mutations in BRCA1 or BRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. (PubMed id 14732925)^{1, 9} Mote P.A....Clarke C.L. (2004)
402. RNA analysis reveals splicing mutations and loss of expression defects in MLH1 and BRCA1. (PubMed id 15300854)^{1, 9} Sharp A.... Eccles D. (2004)
403. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. (PubMed id 15520196)^{1, 9} Bae I....Rosen E.M. (2004)
404. Differential association of BRCA1 and BRCA2 genes with some breast cancer-associated genes in early and late onset breast tumors. (PubMed id 15576832)^{1, 9} Chunder N....Panda C.K. (2004)
405. BRCA1 and BRCA2 mutations in women from Shanghai China. (PubMed id 14973102)^{1, 9} Suter N.M....Ostrander E.A. (2004)
406. Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair. (PubMed id 14701743)^{1, 9} Zhang J....Xia F. (2004)
407. Structure of the BRCT repeats of BRCA1 bound to a BACH1 phosphopeptide: implications for signaling. (PubMed id 15125843)^{1, 9} Shiozaki E.N....Shi Y. (2004)
408. BRCA1-BARD1 complexes are required for p53Ser-15 phosphorylation and a G1/S arrest following ionizing radiation-induced DNA damage. (PubMed id 15159397)^{1, 9} Fabbro M....Khanna K.K. (2004)
409. BRCA1 and p53: compensatory roles in DNA repair. (PubMed id 13679996)^{1, 9} Hartman A.R. and Ford J.M. (2003)
410. A subset of ATM- and ATR-dependent phosphorylation events requires the BRCA1 protein. (PubMed id 12773400)^{1, 9} Foray N....Jeggo P. (2003)
411. BRCA1 splice variants exhibit overlapping and distinct transcriptional transactivation activities. (PubMed id 12682913)^{1, 9} McEachern K.A....Arrick B.A. (2003)
412. Detection of the most frequent mutations in BRCA1 gene on polyacrylamide gels containing Spreadex Polymer NAB. (PubMed id 12937835)^{1, 9} Janatova M....Matous B. (2003)
413. BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations. (PubMed id 12582017)^{1, 9} Ginolhac S.M....Sinilnikova O.M. (2003)
414. Founder mutations in BRCA1/2 are not frequent in Canadian Ashkenazi Jewish men with prostate cancer. (PubMed id 12911837)^{1, 9} Hamel N....Foulkes W.D. (2003)
415. Control of biochemical reactions through supramolecular RING domain self-assembly. (PubMed id 12438698)^{1, 9} Kentsis A....Borden K.L. (2002)
416. The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. (PubMed id 11981002)^{1, 9} Lakhani S.R....Easton D.F. (2002)
417. Transactivation of repair genes by BRCA1. (PubMed id 12496474)^{1, 9} El-Deiry W.S. (2002)
418. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. (PubMed id 12239151)^{1, 9} Taniguchi T.... D'Andrea A.D. (2002)
419. Cancer Incidence in BRCA1 mutation carriers. (PubMed id 12237281)^{1, 9} Thompson D. and Easton D.F. (2002)
420. Mutagen sensitivity of peripheral blood from women carrying a BRCA1 or BRCA2 mutation. (PubMed id 11890937)^{1, 9} Trenz K....Speit G. (2002)
421. Structure of the 53BP1 BRCT region bound to p53 and its comparison to the Brca1 BRCT structure. (PubMed id 11877378)^{1, 9} Joo W.S....Pavletich N.P. (2002)
422. The BRCA1 and BARD1 association with the RNA polymerase II holoenzyme. (PubMed id 12154023)^{1, 9} Chiba N. and Parvin J.D. (2002)
423. Loss of heterozygosity of p53, BRCA1, VHL, and estrogen receptor genes in breast carcinoma: correlation with related protein products and morphologic features. (PubMed id 12490973)^{1, 9} Otis C.N....Merino M.J. (2002)
424. p300 Modulates the BRCA1 inhibition of estrogen receptor activity. (PubMed id 11782371)^{1, 9} Fan S....Rosen E.M. (2002)
425. Breast tumor immunophenotype of BRCA1-mutation carriers is influenced by age at diagnosis. (PubMed id 11448907)^{1, 9} Vaziri S.A....Casey G. (2001)
426. The frequency of the predominant Jewish mutations in BRCA1 and BRCA2 in unselected Ashkenazi colorectal cancer patients. (PubMed id 11207040)^{1, 9} Chen-Shtoyerman R....Theodor L. (2001)
427. Suppression of breast cancer invasion and migration by indole-3-carbinol: associated with up-regulation of BRCA1 and E-cadherin/catenin complexes. (PubMed id 10868478)^{1, 9} Meng Q....Fan S. (2000)
428. Heregulin induces phosphorylation of BRCA1 through phosphatidylinositol 3-Kinase/AKT in breast cancer cells. (PubMed id 10542266)^{1, 9} Altiok S....Avraham H. (1999)
429. The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. (PubMed id 9738006)^{1, 9} Yu X....Baer R. (1998)
430. Dynamic changes of BRCA1 subnuclear location and phosphorylation state are initiated by DNA damage. (PubMed id 9267023)^{1, 9} Scully R....Livingston D.M. (1997)
431. A comparison of BRCA1 nuclear localization with 14 DN A damage response proteins and domains: identification of specific differences between BRCA1 and 53BP1 at DNA damage-induced foci. (PubMed id 19766185)^{1, 9} Mok M.T. and Henderson B.R. (2010)
432. Concomitant loss of heterozygosity at the BRCA1 and F HIT genes as a prognostic factor in sporadic breast cancer. (PubMed id 20417865)^{1, 9} Silva Soares E.W....de Souza Fonseca Ribeiro E.M. (2010)
433. Germline BRCA mutations denote a clinicopathologic su bset of prostate cancer. (PubMed id 20215531)^{1, 9} Gallagher D.J....Offit K. (2010)
434. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. (PubMed id 20453858)^{1, 9} Bouwman P....Jonkers J. (2010)
435. The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer. (PubMed id 20209131)^{1, 9} Margeli M....Rosell R. (2010)
436. BRCA1 regulates acetylation and ubiquitination of est rogen receptor-alpha. (PubMed id 19887647)^{1, 9} Ma Y....Rosen E.M. (2010)
437. DNA methylation profiling in doxorubicin treated prim ary locally advanced breast tumours identifies novel genes associated with surv ival and treatment response. (PubMed id 20338046)^{1, 9} Dejeux E....Tost J. (2010)
438. Characterization of BRCA1 and BRCA2 deleterious mutat ions and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE study. (PubMed id 20104584)^{1, 9} Borg A....Bernstein J.L. (2010)
439. Estrogen receptor positive breast cancers in BRCA1 mu tation carriers: clinical risk factors and pathologic features. (PubMed id 20149218)^{1, 9} Tung N....Schnitt S.J. (2010)
440. HOXA9 regulates BRCA1 expression to modulate human br east tumor phenotype. (PubMed id 20389018)^{1, 9} Gilbert P.M....Weaver V.M. (2010)
441. Polymorphisms in the BRCA1 and ABCB1 genes modulate m enopausal hormone therapy associated breast cancer risk in postmenopausal women . (PubMed id 19672706)^{1, 9} (2010)
442. BRCA1/BARD1 E3 ubiquitin ligase can modify histones H 2A and H2B in the nucleosome particle. (PubMed id 19916563)^{1, 9} Thakar A....Zlatanova J. (2010)
443. Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. (PubMed id 19079346)^{1, 9} Gonzalez M.E....Kleer C.G. (2009)
444. [Analysis of BRCA1 gene mutations in patients with early-onset breast cancer and their affected relatives in Guangdong province] (PubMed id 19246281)^{1, 9} Zhou J....Shao Z.M. (2009)
445. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. (PubMed id 19383374)^{1, 9} Lynch H.T....Godwin A.K. (2009)
446. Role of BRCA1, HSD17B1 and HSD17B2 methylation in bre ast cancer tissue. (PubMed id 19729830)^{1, 9} Bhavani V....Hasan Q. (2009)
447. Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients. (PubMed id 19940364)^{1, 9} Sharma G....Ralhan R. (2009)
448. Sensitivity to first-line chemotherapy for metastatic breast cancer in BRCA1 and BRCA2 mutation carriers. (PubMed id 19564533)^{1, 9} Kriege M....Klijn J.G. (2009)
449. A novel BRCA1 mutation in a Spanish patient with ovarian cancer. (PubMed id 18278587)^{1, 9} Salgado J....GarcA-a-Foncillas J. (2009)
450. Breast cancer immunohistochemical features in young w omen with BRCA 1/2 mutations. (PubMed id 19877382)^{1, 9} Zakhartseva L.M....Shurygina O.V. (2009)
451. CpG island tumor suppressor promoter methylation in non-BRCA-associated early mammary carcinogenesis. (PubMed id 19258476)^{1, 9} Vasilatos S.N....Seewaldt V.L. (2009)
452. [Analysis of K-ras, BRCA1/2, CHEK2 mutations and micr osatellite markers (loss of heterozygosity at 9p, 17p and 18q) in sporadic panc reas adenocarcinomas] (PubMed id 19548527)^{1, 9} Amosenko F.A....Kalinin V.N. (2009)
453. Basal Cytokeratin and Epidermal Growth Factor Receptor Expression Are Not Predictive of BRCA1 Mutation Status in Women With Triple-negative Breast Cancers. (PubMed id 19390427)^{1, 9} Collins L.C....Garber J.E. (2009)
454. Polymorphisms in HPV E6/E7 protein interacted genes a nd risk of cervical cancer in Chinese women: a case-control analysis. (PubMed id 19482343)^{1, 9} Zhou X....Shen H. (2009)
455. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. (PubMed id 19268590)^{1, 9} Zhang F....Yu X. (2009)
456. Sequence variant discovery in DNA repair genes from r adiosensitive and radiotolerant prostate brachytherapy patients. (PubMed id 19638463)^{1, 9} Pugh T.J....Moore R.A. (2009)
457. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. (PubMed id 19064968)^{1, 9} Ferrone C.R....Robson M.E. (2009)
458. Utility of DNA repair protein foci for the detection of putative BRCA1 pathway defects in breast cancer biopsies. (PubMed id 19671671)^{1, 9} Willers H....Powell S.N. (2009)
459. BRCA1 promoter methylation is associated with increas ed mortality among women with breast cancer. (PubMed id 18521744)^{1, 9} Xu X....Chen J. (2009)
460. Ubiquitination and downregulation of BRCA1 by ubiquit in-conjugating enzyme E2T overexpression in human breast cancer cells. (PubMed id 19887602)^{1, 9} Ueki T....Katagiri T. (2009)
461. Premature senescence is a major response to DNA cross -linking agents in BRCA1-defective cells: implication for tailored treatments o f BRCA1 mutation carriers. (PubMed id 19372557)^{1, 9} Santarosa M....Maestro R. (2009)
462. Contribution of BRCA1 germ-line mutations to breast c ancer in Greece: a hospital-based study of 987 unselected breast cancer cases. (PubMed id 19491894)^{1, 9} Armaou S....Konstantopoulou I. (2009)
463. Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer. (PubMed id 19381686)^{1, 9} Graeser M....Schmutzler R.K. (2009)
464. Potential excess mortality in BRCA1/2 mutation carriers beyond breast, ovarian, prostate, and pancreatic cancers, and melanoma. (PubMed id 19277124)^{1, 9} Mai P.L....Wacholder S. (2009)
465. Prolactin blocks nuclear translocation of VDR by regulating its interaction with BRCA1 in osteosarcoma cells. (PubMed id 19074549)^{1, 9} Deng C....Walker A.M. (2009)
466. Inhibition of poly(ADP-ribose) polymerase in tumors f rom BRCA mutation carriers. (PubMed id 19553641)^{1, 9} Fong P.C....de Bono J.S. (2009)
467. A novel deletion of BRCA1 gene that eliminates the ATG initiation codon without affecting the promoter region. (PubMed id 19393826)^{1, 9} Marino M....Calandra S. (2009)
468. BRCA1-associated protein 1 interferes with BRCA1/BARD1 RING heterodimer activity. (PubMed id 19117993)^{1, 9} Nishikawa H....Ohta T. (2009)
469. Inactivation of the Nijmegen breakage syndrome gene leads to excess centrosome duplication via the ATR/BRCA1 pathway. (PubMed id 19244116)^{1, 9} Shimada M....Komatsu K. (2009)
470. XPG mRNA expression levels modulate prognosis in resected non-small-cell lung cancer in conjunction with BRCA1 and ERCC1 expression. (PubMed id 19289372)^{1, 9} Bartolucci R....Rosell R. (2009)
471. Absence of germline BRCA1 mutations in familial pancreatic cancer patients. (PubMed id 19029836)^{1, 9} Axilbund J.E....Klein A.P. (2009)
472. Human SNF5/INI1, a component of the human SWI/SNF chr omatin remodeling complex, promotes nucleotide excision repair by influencing A TM recruitment and downstream H2AX phosphorylation. (PubMed id 19805520)^{1, 9} Ray A....Wani A.A. (2009)
473. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified. (PubMed id 17851763)^{1, 9} Li W.F....Shao Z.M. (2008)
474. Promoter hypermethylation of BRCA1 correlates with absence of expression in hereditary breast cancer tumors. (PubMed id 18567944)^{1, 9} Tapia T....Carvallo P. (2008)
475. BRCA1-mediated ubiquitination inhibits topoisomerase II alpha activity in response to oxidative stress. (PubMed id 18162055)^{1, 9} Shinagawa H....Yoshida K. (2008)
476. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. (PubMed id 17492376)^{1, 9} Byrski T....Lubinski J. (2008)
477. Methylation is less abundant in BRCA1-associated compared with sporadic breast cancer. (PubMed id 18647968)^{1, 9} Suijkerbuijk K.P....van Diest P.J. (2008)
478. On the dynamics of breast tumor development in women carrying germline BRCA1 and BRCA2 mutations. (PubMed id 18098285)^{1, 9} Simon R. and Zhang X. (2008)
479. BRCA1 5083del19 mutant allele selectively up-regulates periostin expression in vitro and in vivo. (PubMed id 18980973)^{1, 9} Quaresima B....Costanzo F. (2008)
480. Gamma-irradiation-induced DNA damage checkpoint activation involves feedback regulation between extracellular signal-regulated kinase 1/2 and BRCA1. (PubMed id 18593910)^{1, 9} Yan Y....Cowan K.H. (2008)
481. Occult fallopian tube cancer in a patient with BRCA1 breast cancer. (PubMed id 18971141)^{1, 9} Brown J.V....Goldstein B.H. (2008)
482. BRCA1 regulates human mammary stem/progenitor cell fate. (PubMed id 18230721)^{1, 9} Liu S....Wicha M.S. (2008)
483. Higher occurrence of childhood cancer in families with germline mutations in BRCA2, MMR and CDKN2A genes. (PubMed id 18481196)^{1, 9} Magnusson S....Olsson H. (2008)
484. Estrogen receptor alpha, BRCA1, and FANCF promoter methylation occur in distinct subsets of sporadic breast cancers. (PubMed id 17932744)^{1, 9} Wei M....Olopade O.I. (2008)
485. BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history. (PubMed id 18431501)^{1, 9} Toh G.T....Teo S.H. (2008)
486. Loss of expression of FANCD2 protein in sporadic and hereditary breast cancer. (PubMed id 17333336)^{1, 9} van der Groep P....van Diest P.J. (2008)
487. Mutation screening of the BRCA1 gene in sporadic breast cancer in southern Chinese populations. (PubMed id 18835712)^{1, 9} Haitian Z....Fuqiang W. (2008)
488. BRCA1 knock-down causes telomere dysfunction in mammary epithelial cells. (PubMed id 19188703)^{1, 9} Cabuy E....Slijepcevic P. (2008)
489. Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance. (PubMed id 18413725)^{1, 9} Swisher E.M....Taniguchi T. (2008)
490. Clinical classification of BRCA1 and BRCA2 DNA sequence variants: the value of cytokeratin profiles and evolutionary analysis--a report from the kConFab Investigators. (PubMed id 18375895)^{1, 9} Spurdle A.B....Goldgar D.E. (2008)
491. Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: evidence from 261 cases in Israel, 1976-1999. (PubMed id 18158280)^{1, 9} Chodick G....Iscovich J. (2008)
492. Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a Clinical Cancer Genetics service setting: risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. (PubMed id 18513387)^{1, 9} Evans D.G....Maher E.R. (2008)
493. Prolonged survival among women with BRCA germline mutations and advanced endometrial cancer: a case series. (PubMed id 17645508)^{1, 9} Kwon J.S....Ainsworth P. (2008)
494. No evidence that GATA3 rs570613 SNP modifies breast cancer risk. (PubMed id 19082709)^{1, 9} Johnatty S.E....Chenevix-Trench G. (2008)
495. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. (PubMed id 18182994)^{1, 9} Mitra A....Eeles R. (2008)
496. Does the nonsense-mediated mRNA decay mechanism prevent the synthesis of truncated BRCA1, CHK2, and p53 proteins? (PubMed id 17694537)^{1, 9} Anczukow O....Mazoyer S. (2008)
497. Occurrence of both breast and ovarian cancer in a woman is a marker for the BRCA gene mutations: a population-based study from western Sweden. (PubMed id 16944270)^{1, 9} Einbeigi Z....Karlsson P. (2007)
498. Estrogen receptor alpha is a putative substrate for the BRCA1 ubiquitin ligase. (PubMed id 17392432)^{1, 9} Eakin C.M....Klevit R.E. (2007)
499. Identification and in silico analysis of functional SNPs of the BRCA1 gene. (PubMed id 17719744)^{1, 9} Rajasekaran R....Sethumadhavan R. (2007)
500. Effects of BRCA1 transgene expression on murine mammary gland development and mutagen-induced mammary neoplasia. (PubMed id 17505536)^{1, 9} Hoshino A....Jensen R.A. (2007)
501. BRCA1a has antitumor activity in TN breast, ovarian and prostate cancers. (PubMed id 17384678)^{1, 9} Yuli C....Rao V.N. (2007)
502. Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy. (PubMed id 17767707)^{1, 9} Palli D....Ottini L. (2007)
503. [Analysis of the mutation of BRCA1 gene in 70 Uigur women breast cancer patients in Xinjiang] (PubMed id 17557253)^{1, 9} Fu X.G....Pang L.J. (2007)
504. The 3' untranslated region C > T polymorphism of prohibitin is a breast cancer risk modifier in Polish women carrying a BRCA1 mutation. (PubMed id 17004108)^{1, 9} Jakubowska A....Hamann U. (2007)
505. [Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and primary multiple tumors involving the ovaries. Patients of Russian population using biochips] (PubMed id 17380889)^{1, 9} Fedorova O.E....Nasedkina T.V. (2007)
506. FANCJ (BACH1) helicase forms DNA damage inducible foci with replication protein A and interacts physically and functionally with the single-stranded DNA-binding protein. (PubMed id 17596542)^{1, 9} Gupta R....Brosh R.M. (2007)
507. Cancer risks in carriers of the BRCA1/2 Ashkenazi founder mutations. (PubMed id 17307836)^{1, 9} Kadouri L....Peretz T. (2007)
508. Ubiquitination and proteasome-mediated degradation of BRCA1 and BARD1 during steroidogenesis in human ovarian granulosa cells. (PubMed id 17185394)^{1, 9} Lu Y....Hu Y. (2007)
509. Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. (PubMed id 17428320)^{1, 9} Broeks A....Van 't Veer L.J. (2007)
510. The BRCA1/2 pathway prevents hematologic cancers in addition to breast and ovarian cancers. (PubMed id 17683622)^{1, 9} Friedenson B. (2007)
511. Tumor suppressor BRCA1 inhibits a breast cancer-associated promoter of the aromatase gene (CYP19) in human adipose stromal cells. (PubMed id 16940470)^{1, 9} Ghosh S....Li R. (2007)
512. Identification of sequences that target BRCA1 to nuclear foci following alkylative DNA damage. (PubMed id 17531442)^{1, 9} Au W.W. and Henderson B.R. (2007)
513. Heterozygote BRCA1 status and skewed chromosome X inactivation. (PubMed id 16944269)^{1, 9} Helbling-Leclere A....Feunteun J. (2007)
514. BRCA1 regulates IFN-gamma signaling through a mechanism involving the type I IFNs. (PubMed id 17374731)^{1, 9} Buckley N.E....Mullan P.B. (2007)
515. Epigenetic inactivation of the chromosomal stability control genes BRCA1, BRCA2, and XRCC5 in non-small cell lung cancer. (PubMed id 17289874)^{1, 9} Lee M.N....Wang Y.C. (2007)
516. A mutation in the 5' untranslated region of the BRCA1 gene in sporadic breast cancer causes downregulation of translation efficiency. (PubMed id 17697535)^{1, 9} Wang J....Ma X. (2007)
517. HIV-1 Vpr induces ATM-dependent cellular signal with enhanced homologous recombination. (PubMed id 16983346)^{1, 9} Nakai-Murakami C....Ishizaka Y. (2007)
518. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer. (PubMed id 18000219)^{1, 9} Hosey A.M....Harkin D.P. (2007)
519. Familial breast/ovarian cancer and BRCA1/2 genetic screening: the role of immunohistochemistry as an additional method in the selection of patients. (PubMed id 17625228)^{1, 9} Vaz F.H....Andre S.P. (2007)
520. Substrates of the BRCA1-dependent ubiquitin ligase. (PubMed id 16479151)^{1, 9} Starita L.M. and Parvin J.D. (2006)
521. Multifactorial contributions to an acute DNA damage response by BRCA1/BARD1-containing complexes. (PubMed id 16391231)^{1, 9} Greenberg R.A....Livingston D.M. (2006)
522. Genetic instability of BRCA1 gene at locus D17S855 is related to clinicopathological behaviors of gastric cancer from Chinese population. (PubMed id 16830385)^{1, 9} Chen X.R....Wang J.W. (2006)
523. Influence of polymorphisms in xenobiotic-metabolizing genes and DNA-repair genes on diepoxybutane-induced SCE frequency. (PubMed id 17078101)^{1, 9} Laczmanska I....Sasiadek M.M. (2006)
524. New role for nuclear hormone receptors and coactivators in regulation of BRCA1-mediated DNA repair in breast cancer cell lines. (PubMed id 16417649)^{1, 9} Crowe D.L. and Lee M.K. (2006)
525. Polymorphisms in genes involved in DNA double-strand break repair pathway and susceptibility to benzene-induced hematotoxicity. (PubMed id 16728435)^{1, 9} Shen M....Smith M.T. (2006)
526. BRCA1 suppresses osteopontin-mediated breast cancer. (PubMed id 16807234)^{1, 9} El-Tanani M.K....Rudland P.S. (2006)
527. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo. (PubMed id 16969499)^{1, 9} Quaresima B....Venuta S. (2006)
528. Analysis of RAD51 polymorphism and BRCA1 mutations in Polish women with breast cancer. (PubMed id 16837909)^{1, 9} Romanowicz-Makowska H....Kulig A. (2006)
529. Lack of germ-line promoter methylation in BRCA1-negative families with familial breast cancer. (PubMed id 17253935)^{1, 9} Chen Y....Ziegler J.L. (2006)
530. A conserved pathway to activate BRCA1-dependent ubiquitylation at DNA damage sites. (PubMed id 16628214)^{1, 9} Polanowska J....Boulton S.J. (2006)
531. BRCA1 negatively regulates the cancer-associated aromatase promoters I.3 and II in breast adipose fibroblasts and malignant epithelial cells. (PubMed id 16940443)^{1, 9} Lu M....Bulun S.E. (2006)
532. An hGCN5/TRRAP histone acetyltransferase complex co-activates BRCA1 transactivation function through histone modification. (PubMed id 16260778)^{1, 9} Oishi H....Kato S. (2006)
533. Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. (PubMed id 16638864)^{1, 9} Damaraju S....Parliament M. (2006)
534. Pathology and gene expression of hereditary breast tumors associated with BRCA1, BRCA2 and CHEK2 gene mutations. (PubMed id 16998498)^{1, 9} Honrado E....Benitez J. (2006)
535. BRCA1/BARD1 ubiquitinate phosphorylated RNA polymerase II. (PubMed id 15886201)^{1, 9} Starita L.M....Chiba N. (2005)
536. Structural determinants of the BRCA1 : estrogen receptor interaction. (PubMed id 15674350)^{1, 9} Ma Y.X....Rosen E.M. (2005)
537. Understanding breast cancer risk -- where do we stand in 2005? (PubMed id 15784178)^{1, 9} Dumitrescu R.G. and Cotarla I. (2005)
538. BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. (PubMed id 16288014)^{1, 9} Kennedy R.D....Harkin D.P. (2005)
539. BRCA1/BARD1 inhibition of mRNA 3' processing involves targeted degradation of RNA polymerase II. (PubMed id 15905410)^{1, 9} Kleiman F.E....Manley J.L. (2005)
540. Use of adenoviral E1A protein to analyze K18 promoter deregulation in colon carcinoma cells discloses a role for CtBP1 and BRCA1. (PubMed id 15831101)^{1, 9} Delouis C....Brison O. (2005)
541. [Genetic instability on chromosome 17q21 in gastric cancer of Chinese patients] (PubMed id 16011248)^{1, 9} Lin X.Q....Li J.C. (2005)
542. Structural basis for cell cycle checkpoint control by the BRCA1-CtIP complex. (PubMed id 16101277)^{2, 9} Varma A.K....Ladias J.A. (2005)
543. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. (PubMed id 15589605)^{1, 9} Metcalfe K.A....Narod S.A. (2005)
544. High proportion of recurrent germline mutations in the BRCA1 gene in breast and ovarian cancer patients from the Prague area. (PubMed id 16168118)^{1, 9} Pohlreich P....Matous B. (2005)
545. Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation. (PubMed id 15894690)^{1, 9} Kowalska E....Lubinski J. (2005)
546. An amino-terminal motif functions as a second nuclear export sequence in BRCA1. (PubMed id 15811849)^{1, 9} Thompson M.E....Holt J.T. (2005)
547. Centrosomal microtubule nucleation activity is inhibited by BRCA1-dependent ubiquitination. (PubMed id 16166645)^{1, 9} Sankaran S....Parvin J.D. (2005)
548. Breast cancer risk following bilateral oophorectomy in BRCA1 and BRCA2 mutation carriers: an international case-control study. (PubMed id 16234515)^{1, 9} Eisen A....Narod S.A. (2005)
549. Recent developments in critical genes in the molecular biology of breast cancer. (PubMed id 15691805)^{1, 9} Sunpaweravong S. and Sunpaweravong P. (2005)
550. Hyperphosphorylation of the BARD1 tumor suppressor in mitotic cells. (PubMed id 15855157)^{1, 9} Choudhury A.D....Baer R. (2005)
551. Germline BRCA1 mutations and G/C polymorphism in the 5'-untranslated region of the RAD51 gene in Polish women with breast cancer. (PubMed id 16477874)^{1, 9} Romanowicz-Makowska H....Kulig A. (2005)
552. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. (PubMed id 15083174)^{1, 9} Olivier R.I....van't Veer L.J. (2004)
553. BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number. (PubMed id 15367667)^{1, 9} Starita L.M....Parvin J.D. (2004)
554. MYC is amplified in BRCA1-associated breast cancers. (PubMed id 14760071)^{1, 9} Grushko T.A....Olopade O.I. (2004)
555. Fidelity of DNA double-strand break repair in heterozygous cell lines harbouring BRCA1 missense mutations. (PubMed id 14647443)^{1, 9} Coupier I....Stoppa-Lyonnet D. (2004)
556. Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase. (PubMed id 14638690)^{1, 9} Nishikawa H....Ohta T. (2004)
557. Microcephalin is a DNA damage response protein involved in regulation of CHK1 and BRCA1. (PubMed id 15220350)^{1, 9} Xu X.... Stern D.F. (2004)
558. Attitudes toward preventive oophorectomy among BRCA1 mutation carriers in Poland. (PubMed id 15053071)^{1, 9} Menkiszak J....Lubinski J. (2004)
559. BRCA1 and BRCA2 mutations as prognostic factors in bilateral breast cancer patients. (PubMed id 15319244)^{1, 9} Rogozinska-Szczepka J....Wojciechowska-L/acka A. (2004)
560. BRCA1 inhibits membrane estrogen and growth factor receptor signaling to cell proliferation in breast cancer. (PubMed id 15199145)^{1, 9} Razandi M....Levin E.R. (2004)
561. Is systemic disease in the coelomic epithelium associated with BRCA1 germline mutations? (PubMed id 15026477)^{4, 9} Pautier P....Spatz A. (2004)
562. Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. (PubMed id 15073127)^{1, 9} Lakhani S.R....Easton D.F. (2004)
563. [A paradox and three egnimas about the role of BRCA1 in breast and ovarian cancers] (PubMed id 15368961)^{1, 9} Feunteun J. (2004)
564. BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study. (PubMed id 15571962)^{1, 9} Rafnar T....Thorlacius S. (2004)
565. Identification of germline 185delAG BRCA1 mutations in non-Jewish Americans of Spanish ancestry from the San Luis Valley, Colorado. (PubMed id 12879478)^{1, 9} Mullineaux L.G....Graw S.L. (2003)
566. BRCA1 in hormone-responsive cancers. (PubMed id 14516936)^{1, 9} Rosen E.M....Goldberg I.D. (2003)
567. BRCA1 gene in breast cancer. (PubMed id 12767038)^{1, 9} Rosen E.M....Goldberg I.D. (2003)
568. A mutation analysis of the BRCA1 gene in 140 families from southeast France with a history of breast and/or ovarian cancer. (PubMed id 12827452)^{1, 9} Rostagno P....Frenay M. (2003)
569. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma. (PubMed id 12640109)^{1, 9} Baldassarre G....Fusco A. (2003)
570. A specific GFP expression assay, penetrance estimate, and histological assessment for a putative splice site mutation in BRCA1. (PubMed id 12815598)^{1, 9} Southey M.C....Armes J.E. (2003)
571. Enhanced sensitivity of peripheral blood lymphocytes from women carrying a BRCA1 mutation towards the mutagenic effects of various cytostatics. (PubMed id 14644329)^{1, 9} Trenz K....Speit G. (2003)
572. BRCT repeats as phosphopeptide-binding modules involved in protein targeting. (PubMed id 14576432)^{1, 9} Manke I.A.... Yaffe M.B. (2003)
573. Mutational analysis of the LMO4 gene, encoding a BRCA1-interacting protein, in breast carcinomas. (PubMed id 12925972)^{1, 9} Sutherland K.D....Campbell I.G. (2003)
574. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. (PubMed id 14519755)^{1, 9} Foulkes W.D....Akslen L.A. (2003)
575. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. (PubMed id 12698198)^{1, 9} Tassone P....Venuta S. (2003)
576. Down-regulation of BRCA1 in BCR-ABL-expressing hematopoietic cells. (PubMed id 12576338)^{1, 9} Deutsch E....Bourhis J. (2003)
577. The role of the breast cancer susceptibility gene 1 (BRCA1) in sporadic epithelial ovarian cancer. (PubMed id 14613551)^{1, 9} McCoy M.L....Roskelley C.D. (2003)
578. The BRCT domain is a phospho-protein binding domain. (PubMed id 14576433)^{1, 9} Yu X.... Chen J. (2003)
579. Androgen pathway dysregulation in BRCA1-mutated breast tumors. (PubMed id 12779088)^{1, 9} Berns E.M....van der Kwast T.H. (2003)
580. BRCA1 and BRCA2 mutations have no major role in predisposition to prostate cancer in Finland. (PubMed id 12920090)^{1, 9} Ikonen T....Schleutker J. (2003)
581. Histopathological characteristics of BRCA1- and BRCA2-associated intraperitoneal cancer: a clinic-based study. (PubMed id 14574155)^{1, 9} Piek J.M....Menko F.H. (2003)
582. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families. (PubMed id 14678969)^{1, 9} Oldenburg R.A....Devilee P. (2003)
583. Association between BRCA1 and BRCA2 mutations and cancer phenotype in Spanish breast/ovarian cancer families: implications for genetic testing. (PubMed id 11802208)^{1, 9} de la Hoya M....Caldes T. (2002)
584. Survival in prospectively ascertained familial breast cancer: analysis of a series stratified by tumour characteristics, BRCA mutations and oophorectomy. (PubMed id 12237897)^{1, 9} Moller P....Heimdal K. (2002)
585. 53BP1, a mediator of the DNA damage checkpoint. (PubMed id 12364621)^{1, 9} Wang B....Elledge S.J. (2002)
586. Frequent loss of BRCA1 nuclear expression in young women with breast cancer: an immunohistochemical study from an area of low incidence but early onset. (PubMed id 12607598)^{1, 9} Lee W.Y. (2002)
587. BRCA1 directs a selective p53-dependent transcriptional response towards growth arrest and DNA repair targets. (PubMed id 12024039)^{1, 9} MacLachlan T.K....El-Deiry W.S. (2002)
588. BRCA1 and BRCA2 mutations in Russian familial breast cancer. (PubMed id 11793480)^{1, 9} Tereschenko I.V....Pharoah P.D. (2002)
589. Mutations in the BRCT domain confer temperature sensitivity to BRCA1 in transcription activation. (PubMed id 12496477)^{1, 9} Carvalho M.A....Monteiro A.N. (2002)
590. Clustering of variations and haplotype analysis in the highly variable region of exon 11 of BRCA1 in Chinese women with sporadic breast cancer. (PubMed id 12402341)^{1, 9} Li Y....Zhang G. (2002)
591. Characterization of 2 novel and 2 recurring BRCA1 germline mutations in breast and/or ovarian carcinoma patients from the area of Naples. (PubMed id 11956590)^{1, 9} Curci A....Viglietto G. (2002)
592. Effects of coping style and BRCA1 and BRCA2 test results on anxiety among women participating in genetic counseling and testing for breast and ovarian cancer risk. (PubMed id 11403219)^{1, 9} Tercyak K.P....Schwartz M.D. (2001)
593. Analysis of murine Brca2 reveals conservation of protein-protein interactions but differences in nuclear localization signals. (PubMed id 11477095)^{1, 9} Sarkisian C.J....Chodosh L.A. (2001)
594. Disruption of BRCA1 LXCXE motif alters BRCA1 functional activity and regulation of RB family but not RB protein binding. (PubMed id 11521194)^{1, 9} Fan S....Rosen E.M. (2001)
595. The BARD1-CstF-50 interaction links mRNA 3' end formation to DNA damage and tumor suppression. (PubMed id 11257228)^{1, 9} Kleiman F.E. and Manley J.L. (2001)
596. Redistribution of BRCA1 among four different protein complexes following replication blockage. (PubMed id 11504724)^{1, 9} Chiba N. and Parvin J.D. (2001)
597. Clinical and pathological features of BRCA1 associated carcinomas in a hospital-based sample of Dutch breast cancer patients. (PubMed id 11720473)^{1, 9} de Bock G.H....van de Vijver M.J. (2001)
598. Adenosine nucleotide modulates the physical interaction between hMSH2 and BRCA1. (PubMed id 11498787)^{1, 9} Wang Q....Greene M.I. (2001)
599. Constitutive activation of JAK-STAT3 signaling by BRCA1 in human prostate cancer cells. (PubMed id 11163768)^{1, 9} Gao B....Fan S. (2001)
600. VCP, a weak ATPase involved in multiple cellular events, interacts physically with BRCA1 in the nucleus of living cells. (PubMed id 10855792)^{1, 9} Zhang H....Greene M.I. (2000)
601. A novel human rad54 homologue, Rad54B, associates with Rad51. (PubMed id 10851248)^{1, 9} Tanaka K....Miyagawa K. (2000)
602. Ataxia telangiectasia-related protein is involved in the phosphorylation of BRCA1 following deoxyribonucleic acid damage. (PubMed id 11016625)^{1, 9} Chen J. (2000)
603. Roles of BRCA1 and its interacting proteins. (PubMed id 10918303)^{1, 9} Deng C.X. and Brodie S.G. (2000)
604. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. (PubMed id 10959836)^{1, 9} Paull T.T....Bonner W.M. (2000)
605. Identification of a functional nuclear export sequence in BRCA1. (PubMed id 10991937)^{1, 9} Rodriguez J.A. and Henderson B.R. (2000)
606. Nuclear localization and cell cycle-specific expression of CtIP, a protein that associates with the BRCA1 tumor suppressor. (PubMed id 10764811)^{1, 9} Yu X. and Baer R. (2000)
607. Screening for germ-line rearrangements and regulatory mutations in BRCA1 led to the identification of four new deletions. (PubMed id 9927062)^{1, 9} Puget N....Mazoyer S. (1999)
608. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. (PubMed id 10426999)^{1, 9} Zhong Q.... Lee W.-H. (1999)
609. Substrate specificities and identification of putative substrates of ATM kinase family members. (PubMed id 10608806)^{1, 9} Kim S.-T.... Kastan M.B. (1999)
610. Requirement of ATM-dependent phosphorylation of brca1 in the DNA damage response to double-strand breaks. (PubMed id 10550055)^{1, 9} Cortez D.... Elledge S.J. (1999)
611. BRCA1 is phosphorylated at serine 1497 in vivo at a cyclin-dependent kinase 2 phosphorylation site. (PubMed id 10373534)^{1, 9} Ruffner H....Verma I.M. (1999)
612. Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells. (PubMed id 9774970)^{1, 9} Chen J....Scully R. (1998)
613. A breast cancer patient of Scottish descent with germ-line mutations in BRCA1 and BRCA2. (PubMed id 9585617)^{1, 9} Liede A....Narod S.A. (1998)
614. BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. (PubMed id 9764635)^{1, 9} Bandera C.A....Mok S.C. (1998)
615. Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. (PubMed id 9625172)^{1, 9} Schorge J.O....Mok S.C. (1998)
616. Frequently occurring germ-line mutations of the BRCA1 gene in ovarian cancer families from Russia. (PubMed id 9150173)^{1, 9} Gayther S.A....Ponder B.A. (1997)
617. BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen. (PubMed id 8895509)^{1, 9} Spillman M.A. and Bowcock A.M. (1996)
618. Germ-line BRCA1 mutations in selected men with prostate cancer. (PubMed id 8644752)^{1, 9} Langston A.A....Ostrander E.A. (1996)
619. BRCA1, TP53, and CHEK2 germline mutations in uterine s erous carcinoma. (PubMed id 22811390)¹ Pennington K.P....Swisher E.M. (2013)
620. BRCA1 immunohistochemistry in a molecularly characteri zed cohort of ovarian high-grade serous carcinomas. (PubMed id 23232854)¹ Garg K....Soslow R.A. (2013)
621. Clinical characteristics and outcomes of BRCA-associat ed ovarian cancer: genotype and survival. (PubMed id 22429596)¹ Liu J....Weitzel J.N. (2012)
622. Can soy phytoestrogens decrease DNA methylation in BRC A1 and BRCA2 oncosuppressor genes in breast cancer? (PubMed id 22339411)¹ Bosviel R....Bernard-Gallon D. (2012)
623. Id4 protein is highly expressed in triple-negative bre ast carcinomas: possible implications for BRCA1 downregulation. (PubMed id 22538771)¹ Wen Y.H....Brogi E. (2012)
624. Predictive value of MGMT, hMLH1, hMSH2 and BRCA1 prote in expression for pathological complete response to neoadjuvant chemotherapy in basal-like breast cancer patients. (PubMed id 22083523)¹ Nakai K....Kasumi F. (2012)
625. Anthropometric measures and risk of ovarian cancer amo ng BRCA1 and BRCA2 mutation carriers. (PubMed id 22262156)¹ McGee J....Narod S.A. (2012)
626. Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi J ewish families with breast and pancreatic cancer. (PubMed id 21598239)¹ Stadler Z.K....Robson M.E. (2012)
627. Multimodel assessment of BRCA1 mutations in Taiwanese (ethnic Chinese) women with early-onset, bilateral or familial breast cancer. (PubMed id 22277901)¹ Kuo W.H....Chang K.J. (2012)
628. BRCA1 and BRCA2 germline mutations in 85 Iranian breas t cancer patients. (PubMed id 21918854)¹ Keshavarzi F....Zeinali S. (2012)
629. BRCA1 and BRCA2 unclassified variants and missense pol ymorphisms in Algerian breast/ovarian cancer families. (PubMed id 22684231)¹ Cherbal F....Maillet P. (2012)
630. Functional dissection of lysine deacetylases reveals t hat HDAC1 and p300 regulate AMPK. (PubMed id 22318606)¹ Lin Y.Y....Boeke J.D. (2012)
631. Morphologic patterns associated with BRCA1 and BRCA2 g enotype in ovarian carcinoma. (PubMed id 22193042)¹ Soslow R.A....Levine D.A. (2012)
632. Full-exon pyrosequencing screening of BRCA germline mu tations in Mexican women with inherited breast and ovarian cancer. (PubMed id 22655046)¹ Vaca-Paniagua F....Perez-Plasencia C. (2012)
633. Canonical Wnt signaling regulates Slug activity and li nks epithelial-mesenchymal transition with epigenetic Breast Cancer 1, Early Ons et (BRCA1) repression. (PubMed id 23011797)¹ Wu Z.Q....Weiss S.J. (2012)
634. Chromosomal instability induced by mammography X-rays in primary human fibroblasts from BRCA1 and BRCA2 mutation carriers. (PubMed id 22788243)¹ Frankenberg-Schwager M. and Gregus A. (2012)
635. Gene-gene interactions in breast cancer susceptibility . (PubMed id 22072393)¹ Turnbull C....Rahman N. (2012)
636. Association of BRCA1 functional single nucleotide poly morphisms with risk of differentiated thyroid carcinoma. (PubMed id 22136207)¹ Xu L....Sturgis E.M. (2012)
637. Charting the landscape of tandem BRCT domain-mediated protein interactions. (PubMed id 22990118)¹ Woods N.T....Monteiro A.N. (2012)
638. Evolutionary constraint helps unmask a splicing regula tory region in BRCA1 exon 11. (PubMed id 22615956)¹ Raponi M....Baralle D. (2012)
639. BRCA-1 promoter hypermethylation and silencing induced by the aromatic hydrocarbon receptor-ligand TCDD are prevented by resveratrol i n MCF-7 cells. (PubMed id 22197621)¹ Papoutsis A.J....Romagnolo D.F. (2012)
640. Integration of BRCA1-mediated miRNA and mRNA profiles reveals microRNA regulation of TRAF2 and NFkB pathway. (PubMed id 22167321)¹ Tanic M....Martinez-Delgado B. (2012)
641. Rap80 protein recruitment to DNA double-strand breaks requires binding to both small ubiquitin-like modifier (SUMO) and ubiquitin conj ugates. (PubMed id 22689573)¹ Hu X....Wang B. (2012)
642. Tubal epithelial lesions in salpingo-oophorectomy spec imens of BRCA-mutation carriers and controls. (PubMed id 22710074)¹ Mingels M.J....Bol M. (2012)
643. Effects of BRCA1 and BRCA2 mutations on female fertili ty. (PubMed id 21993507)¹ Smith K.R....Buys S.S. (2012)
644. Prevalence and characterization of BRCA1 and BRCA2 ger mline mutations in Chinese women with familial breast cancer. (PubMed id 21614564)¹ Zhang J....Xie Y. (2012)
645. Characteristics and spectrum of BRCA1 and BRCA2 mutati ons in 3,922 Korean patients with breast and ovarian cancer. (PubMed id 22798144)¹ Kim H....Haffty B.G. (2012)
646. Transcriptional down-regulation of Brca1 and E-cadheri n by CtBP1 in breast cancer. (PubMed id 21681822)¹ Deng Y....Zhang Q. (2012)
647. BRCA1--conductor of the breast stem cell orchestra: th e role of BRCA1 in mammary gland development and identification of cell of origi n of BRCA1 mutant breast cancer. (PubMed id 22426855)¹ Buckley N.E. and Mullan P.B. (2012)
648. A distinct replication fork protection pathway connect s Fanconi anemia tumor suppressors to RAD51-BRCA1/2. (PubMed id 22789542)¹ Schlacher K....Jasin M. (2012)
649. Differences in natural history between breast cancers in BRCA1 and BRCA2 mutation carriers and effects of MRI screening-MRISC, MARIBS, and Canadian studies combined. (PubMed id 22744338)¹ Heijnsdijk E.A....de Koning H.J. (2012)
650. Breast cancer 1 (BrCa1) may be behind decreased lipoge nesis in adipose tissue from obese subjects. (PubMed id 22666314)¹ Ortega F.J....Fernandez-Real J.M. (2012)
651. Yin Yang 1 positively regulates BRCA1 and inhibits mam mary cancer formation. (PubMed id 21666725)¹ Lee M.H....Deng C.X. (2012)
652. DNA methylation of circulating DNA: a marker for monit oring efficacy of neoadjuvant chemotherapy in breast cancer patients. (PubMed id 22744714)¹ Sharma G....Ralhan R. (2012)
653. Association of death receptor 4 variant (683A > C) with ovarian cancer risk in BRCA1 mutation carriers. (PubMed id 21484799)¹ Dick M.G....Schmutzler R.K. (2012)
654. High frequency of allelic loss at the BRCA1 locus in o varian cancers: clinicopathologic and molecular associations. (PubMed id 22469508)¹ Rzepecka I.K....Kupryjanczyk J. (2012)
655. [Prevalence of mutations BRCA1 5382insC, and CHEK2 110 0delC in the population of Siberian region]. (PubMed id 22946335)¹ Chasovnikova O.B....Liakhovich V.V. (2012)
656. Three novel BRCA1/BRCA2 mutations in breast/ovarian ca ncer families in Croatia. (PubMed id 22366370)¹ Levanat S....Eljuga D. (2012)
657. MDC1 and RNF8 function in a pathway that directs BRCA1 -dependent localization of PALB2 required for homologous recombination. (PubMed id 23038782)¹ Zhang F....Andreassen P.R. (2012)
658. The retinoblastoma gene undergoes rearrangements in BR CA1-deficient basal-like breast cancer. (PubMed id 22706203)¹ Jonsson G....Borg A. (2012)
659. Contribution of epigenetic alteration of BRCA1 and BRC A2 genes in breast carcinomas in Tunisian patients. (PubMed id 21978880)¹ Ben Gacem R....Trimeche M. (2012)
660. Evolutionary pathways in BRCA1-associated breast tumor s. (PubMed id 22628410)¹ Martins F.C....Polyak K. (2012)
661. Impact of intertumoral heterogeneity on predicting che motherapy response of BRCA1-deficient mammary tumors. (PubMed id 22396490)¹ Rottenberg S....Borst P. (2012)
662. Role of BRCA1 in controlling mitotic arrest in ovarian cystadenoma cells. (PubMed id 21792894)¹ Yu V.M....Dubeau L. (2012)
663. DNA-testing for BRCA1/2 prior to genetic counselling i n patients with breast cancer: design of an intervention study, DNA-direct. (PubMed id 22569005)¹ Sie A.S....Hoogerbrugge N. (2012)
664. c-Kit is required for growth and survival of the cells of origin of Brca1-mutation-associated breast cancer. (PubMed id 21765473)¹ Regan J.L....Smalley M.J. (2012)
665. BRCAness: finding the Achilles heel in ovarian cancer. (PubMed id 22673632)¹ Rigakos G. and Razis E. (2012)
666. BRCA1 and BRCA2 mutations correlate with TP53 abnormal ities and presence of immune cell infiltrates in ovarian high-grade serous carci noma. (PubMed id 22282309)¹ McAlpine J.N....Gilks C.B. (2012)
667. BRCA1 and BRCA2 mutations among ovarian cancer patient s from Colombia. (PubMed id 22044689)¹ Rodriguez A.O....Narod S.A. (2012)
668. BRCA1 testing should be offered to individuals with tr iple-negative breast cancer diagnosed below 50 years. (PubMed id 22333603)¹ Robertson L.... . (2012)
669. Rare germline large rearrangements in the BRCA1/2 gene s and eight candidate genes in 472 patients with breast cancer predisposition. (PubMed id 22476849)¹ Rouleau E....Lidereau R. (2012)
670. Somatic mutations in the BRCA1 gene in Chinese women w ith sporadic breast cancer. (PubMed id 22116506)¹ Zhang M....Xie Y. (2012)
671. Promoter hypermethylation patterns in fallopian tube e pithelium of BRCA1 and BRCA2 germ line mutation carriers. (PubMed id 22143498)¹ Bijron J.G....van Diest P.J. (2012)
672. Pathologic features and immunophenotype of estrogen re ceptor-positive breast cancers in BRCA1 mutation carriers. (PubMed id 22613997)¹ Kaplan J.S....Tung N.M. (2012)
673. BRCA1-mediated signaling pathways in ovarian carcinoge nesis. (PubMed id 21887486)¹ Karve T.M....Saha T. (2012)
674. The BRCA1 alternative splicing variant D14-15 with an in-frame deletion of part of the regulatory serine-containing domain (SCD) impai rs the DNA repair capacity in MCF-7 cells. (PubMed id 22245140)¹ Sevcik J....Kleibl Z. (2012)
675. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 m utation carrier families: is the risk increased in non-carriers? (PubMed id 22113258)¹ Bernholtz S....Friedman E. (2012)
676. Synthetic lethality of PARP inhibition in BRCA-network disrupted tumor cells is associated with interferon pathway activation and enha nced by interferon-g. (PubMed id 22392482)¹ Warrener P....Carleton M. (2012)
677. Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers. (PubMed id 21984204)¹ Bernholtz S....Friedman E. (2012)
678. The F-box protein FBXO44 mediates BRCA1 ubiquitination and degradation. (PubMed id 23086937)¹ Lu Y....Hu Y. (2012)
679. BRCA1 is an essential mediator of vinorelbine-induced apoptosis in mesothelioma. (PubMed id 22190288)¹ Busacca S....Fennell D.A. (2012)
680. Prevalence of BRCA1 and BRCA2 mutations in non-familia l breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study. (PubMed id 22382806)¹ Son B.H....Yang J.H. (2012)
681. Analysis of centrosome localization of BRCA1 and its a ctivity in suppressing centrosomal aster formation. (PubMed id 22833046)¹ Tarapore P....Fukasawa K. (2012)
682. Impact of lifestyle factors on preneoplastic changes i n prophylactic oophorectomies of BRCA mutation carriers. (PubMed id 22252303)¹ Primas H....Wagner And The Austrian Hereditary Breast And Ovar ian Cancer Group T. (2012)
683. Common BRCA1 and BRCA2 mutations in breast cancer fami lies: a meta-analysis from systematic review. (PubMed id 21643751)¹ Wang F....Fan X. (2012)
684. Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management. (PubMed id 22535016)¹ Heidemann S....Arnold N.K. (2012)
685. Contribution of germline mutations in the BRCA and PAL B2 genes to pancreatic cancer in Italy. (PubMed id 21989927)¹ Ghiorzo P....Bianchi Scarra G. (2012)
686. Recognizing BRCA gene mutation risk subsequent to brea st cancer diagnosis in southwestern Ontario. (PubMed id 22734169)¹ Vanstone M....Brackstone M. (2012)
687. BRCA1 promoter methylation in peripheral blood DNA was identified in sporadic breast cancer and controls. (PubMed id 22402307)¹ Bosviel R....Bernard-Gallon D.J. (2012)
688. Low prevalence of BRCA1 and BRCA2 mutations in the spo radic breast cancer of Spanish population. (PubMed id 21918853)¹ de Juan Jimenez I....Bolufer Gilabert P. (2012)
689. Dynamic coregulatory complex containing BRCA1, E2F1 an d CtIP controls ATM transcription. (PubMed id 22832221)¹ Moiola C....De Siervi A. (2012)
690. Hereditary breast cancer in Middle Eastern and North A frican (MENA) populations: identification of novel, recurrent and founder BRCA1 mutations in the Tunisian population. (PubMed id 21603858)¹ Mahfoudh W....Chouchane L. (2012)
691. Recurrent germline mutations in BRCA1 and BRCA2 genes in high risk families in Israel. (PubMed id 22399190)¹ Laitman Y....Friedman E. (2012)
692. The KL-VS sequence variant of Klotho and cancer risk i n BRCA1 and BRCA2 mutation carriers. (PubMed id 22212556)¹ Laitman Y....Friedman E. (2012)
693. Breast cancer patients with hypermethylation in the pr omoter of BRCA1 gene exhibit favorable clinical status. (PubMed id 22103901)¹ Krasteva M.E....Angelov S.G. (2012)
694. Functional differences among BRCA1 missense mutations in the control of centrosome duplication. (PubMed id 21725363)¹ Kais Z....Parvin J.D. (2012)
695. Prevalence of BRCA1/2 mutations in sporadic breast/ova rian cancer patients and identification of a novel de novo BRCA1 mutation in a p atient diagnosed with late onset breast and ovarian cancer: implications for gen etic testing. (PubMed id 21553119)¹ De Leeneer K....Claes K. (2012)
696. Identification of the prevalent BRCA1 and BRCA2 mutati ons in the female population of Puerto Rico. (PubMed id 22682623)¹ Dutil J....Echenique M. (2012)
697. BRCA1 regulates microRNA biogenesis via the DROSHA mic roprocessor complex. (PubMed id 22492723)¹ Kawai S. and Amano A. (2012)
698. Recurrent BRCA1 and BRCA2 mutations in breast cancer p atients of African ancestry. (PubMed id 22739995)¹ Zhang J....Olopade O.I. (2012)
699. Prediction of BRCA1 germline mutation status in women with ovarian cancer using morphology-based criteria: identification of a BRCA1 o varian cancer phenotype. (PubMed id 22790858)¹ Fujiwara M....Longacre T.A. (2012)
700. Nucleolar exit of RNF8 and BRCA1 in response to DNA da mage. (PubMed id 22814251)¹ Guerra-Rebollo M....Thomson T.M. (2012)
701. BRCA1 and GATA3 corepress FOXC1 to inhibit the pathoge nesis of basal-like breast cancers. (PubMed id 22120723)¹ Tkocz D....Mullan P.B. (2012)
702. Non-cancer endpoints in BRCA1/2 carriers after risk-re ducing salpingo-oophorectomy. (PubMed id 21898151)¹ Cohen J.V....Domchek S.M. (2012)
703. Targeting BRCA1 localization to augment breast tumor s ensitivity to poly(ADP-Ribose) polymerase inhibition. (PubMed id 22962264)¹ Yang E.S....Xia F. (2012)
704. Pathology of breast and ovarian cancers among BRCA1 an d BRCA2 mutation carriers: results from the Consortium of Investigators of Modif iers of BRCA1/2 (CIMBA). (PubMed id 22144499)¹ Mavaddat N....Antoniou A.C. (2012)
705. Peritoneal washing cytology in patients with BRCA1 or BRCA2 mutations undergoing risk-reducing salpingo-oophorectomies: a 10-year expe rience and reappraisal of its clinical utility. (PubMed id 22425664)¹ Landon G....Sneige N. (2012)
706. BRCA1 is expressed in uterine serous carcinoma (USC) a nd controls insulin-like growth factor I receptor (IGF-IR) gene expression in US C cell lines. (PubMed id 22635027)¹ Amichay K....Bruchim I. (2012)
707. BRCA1/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells. (PubMed id 22431556)¹ Shimizu Y....Elshamy W.M. (2012)
708. Plasma micronutrients, trace elements, and breast canc er in BRCA1 mutation carriers: an exploratory study. (PubMed id 22576580)¹ Kotsopoulos J....Lubinski J. (2012)
709. Characterization of BRCA1 and BRCA2 splicing variants: a collaborative report by ENIGMA consortium members. (PubMed id 21769658)¹ Thomassen M....Vega A. (2012)
710. The C-terminal proteolytic fragment of the breast canc er susceptibility type 1 protein (BRCA1) is degraded by the N-end rule pathway. (PubMed id 22262859)¹ Xu Z....Fahlman R.P. (2012)
711. Germline BRCA1 mutations increase prostate cancer risk . (PubMed id 22516946)¹ Leongamornlert D....Kote-Jarai Z. (2012)
712. High prevalence of BRCA1 and BRCA2 mutations in unsele cted Nigerian breast cancer patients. (PubMed id 22034289)¹ Fackenthal J.D....Olopade O.I. (2012)
713. BRCA1 R1699Q variant displaying ambiguous functional a brogation confers intermediate breast and ovarian cancer risk. (PubMed id 22889855)¹ Spurdle A.B....Goldgar D.E. (2012)
714. BRCA1 requirement for the fidelity of plasmid DNA doub le-strand break repair in cultured breast epithelial cells. (PubMed id 22170030)¹ Thompson E.G....Dixon K. (2012)
715. The in vivo dynamic organization of BRCA1-A complex pr oteins at DNA damage-induced nuclear foci. (PubMed id 22420687)¹ Mok M.T. and Henderson B.R. (2012)
716. NF-kB regulates DNA double-strand break repair in conj unction with BRCA1-CtIP complexes. (PubMed id 21908405)¹ Volcic M....Wiesmuller L. (2012)
717. Unravelling modifiers of breast and ovarian cancer ris k for BRCA1 and BRCA2 mutation carriers: update on genetic modifiers. (PubMed id 22443199)¹ Barnes D.R. and Antoniou A.C. (2012)
718. Loss of heterozygosity at BRCA1 locus is significantly associated with aggressiveness and poor prognosis in breast cancer. (PubMed id 22179631)¹ Okada S....Maehara Y. (2012)
719. Prevalence of BRCA mutations in an unselected populati on of triple-negative breast cancer. (PubMed id 22614657)¹ Hartman A.R....Sandbach J.F. (2012)
720. Changes in the expression of plasma proteins associate d with thrombosis in BRCA1 mutation carriers. (PubMed id 22311183)¹ Custodio A....Perez-Segura P. (2012)
721. Systematic analysis of dimeric E3-RING interactions re veals increased combinatorial complexity in human ubiquitination networks. (PubMed id 22493164)¹ Woodsmith J....Sanderson C.M. (2012)
722. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer. (PubMed id 22406760)¹ Dann R.B....Krivak T.C. (2012)
723. Tissue-based predictors of germ-line BRCA1 mutations: implications for triaging of genetic testing. (PubMed id 22591913)¹ de la Cruz J....Gilcrease M.Z. (2012)
724. A DNA-damage selective role for BRCA1 E3 ligase in cla spin ubiquitylation, CHK1 activation, and DNA repair. (PubMed id 22863316)¹ Sato K....Venkitaraman A.R. (2012)
725. Incorporating information regarding preimplantation ge netic diagnosis into discussions concerning testing and risk management for BRCA 1/2 mutations: a qualitative study of patient preferences. (PubMed id 22736296)¹ Hurley K....Offit K. (2012)
726. A whole-genome massively parallel sequencing analysis of BRCA1 mutant oestrogen receptor-negative and -positive breast cancers. (PubMed id 22362584)¹ Natrajan R....Reis-Filho J.S. (2012)
727. Characterization of BRCA1 protein targeting, dynamics, and function at the centrosome: a role for the nuclear export signal, CRM1, and Aurora A kinase. (PubMed id 22262852)¹ Brodie K.M. and Henderson B.R. (2012)
728. BRCA1 regulates follistatin function in ovarian cancer and human ovarian surface epithelial cells. (PubMed id 22685544)¹ Karve T.M....Saha T. (2012)
729. BRCA1 and HSP90 cooperate in homologous and non-homolo gous DNA double-strand-break repair and G2/M checkpoint activation. (PubMed id 22869732)¹ Stecklein S.R....Jensen R.A. (2012)
730. Loss of BRCA1-A complex function in RAP80 null tumor c ells. (PubMed id 22792303)¹ Bian C....Yu X. (2012)
731. Allelic transcripts dosage effect in morphologically n ormal ovarian cells from heterozygous carriers of a BRCA1/2 French Canadian foun der mutation. (PubMed id 22401979)¹ Abd-Rabbo D....Maugard C.M. (2012)
732. BRCAness profile of sporadic ovarian cancer predicts d isease recurrence. (PubMed id 22253870)¹ Wysham W.Z....Pejovic T. (2012)
733. Activation of the BRCA1/Chk1/p53/p21(Cip1/Waf1) pathwa y by nitric oxide and cell cycle arrest in human neuroblastoma NB69 cells. (PubMed id 22401965)¹ Wouwer M.V....Villalobo A. (2012)
734. Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifier s of BRCA1/2. (PubMed id 22768030)¹ Kirchhoff T....Easton D.F. (2012)
735. BRCA1-IRIS overexpression promotes formation of aggres sive breast cancers. (PubMed id 22511931)¹ Shimizu Y....ElShamy W.M. (2012)
736. BRCA1-mediated repression of mutagenic end-joining of DNA double-strand breaks requires complex formation with BACH1. (PubMed id 22032289)¹ Dohrn L....Wiesmuller L. (2012)
737. Association between BRCA1 and BRCA2 mutations and sur vival in women with invasive epithelial ovarian cancer. (PubMed id 22274685)¹ Bolton K.L....KjA (2012)
738. Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. (PubMed id 22579790)¹ Hyman D.M....Levine D.A. (2012)
739. BRCA1 and BRCA2 germline mutations in Moroccan breast/ ovarian cancer families: novel mutations and unclassified variants. (PubMed id 22425665)¹ Tazzite A....Caligo M.A. (2012)
740. RNF8 regulates assembly of RAD51 at DNA double-strand breaks in the absence of BRCA1 and 53BP1. (PubMed id 22865450)¹ Nakada S.... Matsuo K. (2012)
741. Assessing the RNA effect of 26 DNA variants in the BRC A1 and BRCA2 genes. (PubMed id 21735045)¹ Menendez M....Lazaro C. (2012)
742. Predictive factors for BRCA1/BRCA2 mutations in women with ductal carcinoma in situ. (PubMed id 22009639)¹ Bayraktar S....Arun B. (2012)
743. Germline mutations in the DNA damage response genes BR CA1, BRCA2, BARD1 and TP53 in patients with therapy related myeloid neoplasms. (PubMed id 22652532)¹ Schulz E....Sill H. (2012)
744. Clinical implications for BRCA gene mutation in breast cancer. (PubMed id 21691706)¹ Xu J....Zhang S. (2012)
745. Risk of ipsilateral breast cancer in BRCA1 and BRCA2 mutation carriers. (PubMed id 21221768)¹ Metcalfe K....Narod S.A. (2011)
746. A high response rate to liposomal doxorubicin is seen among women with BRCA mutations treated for recurrent epithelial ovarian cance r. (PubMed id 21945552)¹ Adams S.F....Rubin S.C. (2011)
747. Methylation-related mutations in the BRCA1 promoter i n peripheral blood cells from cancer-free women. (PubMed id 21537840)¹ Al-Moghrabi N....Aboussekhra A. (2011)
748. Adequacy of risk-reducing gynaecologic surgery in BRC A1 or BRCA2 mutation carriers and other women at high risk of pelvic serous can cer. (PubMed id 21424757)¹ Kiely B.E....Phillips K.A. (2011)
749. Ubc9 mediates nuclear localization and growth suppres sion of BRCA1 and BRCA1a proteins. (PubMed id 21344391)¹ Qin Y....Rao V.N. (2011)
750. Risk-reducing salpingo-oophorectomy (RRSO) in BRCA mu tation carriers: experience with a consecutive series of 111 patients using a s tandardized surgical-pathological protocol. (PubMed id 21670699)¹ Powell C.B....Ziegler J. (2011)
751. The relevance of BRCA genetics to prostate cancer path ogenesis and treatment. (PubMed id 22252577)¹ Sundararajan S....Goodman O.B. (2011)
752. Hypoxia-induced epigenetic regulation and silencing o f the BRCA1 promoter. (PubMed id 21670155)¹ Lu Y....Glazer P.M. (2011)
753. A novel role for BRCA1 in regulating breast cancer ce ll spreading and motility. (PubMed id 21282464)¹ Coene E.D....Vaux D.J. (2011)
754. Expression of the stem cell marker ALDH1 in BRCA1 rel ated breast cancer. (PubMed id 21336637)¹ Heerma van Voss M.R....van Diest P.J. (2011)
755. The DeltaNp63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer. (PubMed id 21363924)¹ Buckley N.E....Mullan P.B. (2011)
756. BRCA1 loss induces GADD153-mediated doxorubicin resis tance in prostate cancer. (PubMed id 21700680)¹ De Luca P....De Siervi A. (2011)
757. Screening of 1331 Danish breast and/or ovarian cancer families identified 40 novel BRCA1 and BRCA2 mutations. (PubMed id 21318380)¹ Hansen T.V....Nielsen F.C. (2011)
758. Cancer-specific methylation in the BRCA1 promoter in sporadic breast tumours. (PubMed id 20135363)¹ Ali A.B....Sng J.H. (2011)
759. Targeting the Akt/mTOR pathway in Brca1-deficient can cers. (PubMed id 21242970)¹ Xiang T....Yang Q. (2011)
760. Large genomic rearrangements of the BRCA1 and BRCA2 g enes: review of the literature and report of a novel BRCA1 mutation. (PubMed id 20232141)¹ Sluiter M.D. and van Rensburg E.J. (2011)
761. A proteome-wide, quantitative survey of in vivo ubiqui tylation sites reveals widespread regulatory roles. (PubMed id 21890473)¹ Wagner S.A....Choudhary C. (2011)
762. Regulation of the BRCA1 gene by an SRC3/53BP1 complex . (PubMed id 21914189)¹ Corkery D....Torchia J. (2011)
763. Stumbling blocks on the path to personalized medicine in breast cancer: the case of PARP inhibitors for BRCA1/2-associated cancers. (PubMed id 22586318)¹ Balmana J....Garber J.E. (2011)
764. Human BRCA1-associated breast cancer: no increase in numerical chromosomal instability compared to sporadic tumors. (PubMed id 22024613)¹ Focken T....Gadzicki D. (2011)
765. Risk of contralateral breast cancer associated with c ommon variants in BRCA1 and BRCA2: potential modifying effect of BRCA1/BRCA2 mu tation carrier status. (PubMed id 21161372)¹ Figueiredo J.C....Bernstein J.L. (2011)
766. [Relationship between BRCA1 mRNA expression in tumor c ells from malignant effusions and chemosensitivity to cisplatin in patients with metastatic malignant effusions]. (PubMed id 21875488)¹ Qian X.P....Zou Z.Y. (2011)
767. Factors associated with an individuals' decision to w ithdraw from genetic counseling for BRCA1 and BRCA2 genes mutations: are person ality traits involved? (PubMed id 21604195)¹ Caruso A....Savarese A. (2011)
768. Pathology of hereditary breast cancer. (PubMed id 21336636)¹ van der Groep P....van Diest P.J. (2011)
769. Constitutional methylation of the BRCA1 promoter is s pecifically associated with BRCA1 mutation-associated pathology in early-onset breast cancer. (PubMed id 20978112)¹ Wong E.M....Dobrovic A. (2011)
770. Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk. (PubMed id 21191178)¹ Pelletier C....Weidhaas J.B. (2011)
771. The expression of ERCC1, RRM1, and BRCA1 in breast ca ncer according to the immunohistochemical phenotypes. (PubMed id 21394302)¹ Kim D....Koo J.S. (2011)
772. Morphological predictors of BRCA1 germline mutations in young women with breast cancer. (PubMed id 21343941)¹ Southey M.C....Hopper J.L. (2011)
773. Report of Endometrial Cancer in Australian BRCA1 and BRCA2 mutation-positive Families. (PubMed id 21425892)¹ Duffy D.L....Spurdle A.B. (2011)
774. BRCA1 suppresses the expression of survivin and promo tes sensitivity to paclitaxel through the calcium sensing receptor (CaSR) in hu man breast cancer cells. (PubMed id 21296416)¹ Promkan M....Chakrabarty S. (2011)
775. Haplotype structure in Ashkenazi Jewish BRCA1 and BRC A2 mutation carriers. (PubMed id 21597964)¹ Im K.M....Gold B. (2011)
776. BRCA1 promoter methylation in peripheral blood cells i s associated with increased risk of breast cancer with BRCA1 promoter methylatio n. (PubMed id 20882403)¹ Iwamoto T....Noguchi S. (2011)
777. Oncogenic RAS regulates BRIP1 expression to induce di ssociation of BRCA1 from chromatin, inhibit DNA repair, and promote senescence. (PubMed id 22137763)¹ Tu Z....Zhang R. (2011)
778. Genomic instability, defective spermatogenesis, immuno deficiency, and cancer in a mouse model of the RIDDLE syndrome. (PubMed id 21552324)¹ Bohgaki T....Hakem R. (2011)
779. Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. (PubMed id 22110403)¹ Maxwell C.A....Pujana M.A. (2011)
780. Mutational screening of the BRCA1 gene in sporadic br east cancer in Kazakhstan population. (PubMed id 21410590)¹ Akilzhanova A....Sekine I. (2011)
781. Peripheral blood DNA methylation detected in the BRCA 1 or BRCA2 promoter for sporadic ovarian cancer patients and controls. (PubMed id 21557934)¹ Bosviel R....Bernard-Gallon D.J. (2011)
782. Interaction between the helicases genetically linked to Fanconi anemia group J and Bloom's syndrome. (PubMed id 21240188)¹ Suhasini A.N....Brosh R.M. (2011)
783. CDC25A, VAV1, TP73, BRCA1 and ZAP70 gene overexpressi on correlates with radiation response in colorectal cancer. (PubMed id 21344162)¹ Huang M.Y....Lin S.R. (2011)
784. ERCC1, RRM1 and BRCA1 mRNA expression levels and clini cal outcome of advanced non-small cell lung cancer. (PubMed id 20467918)¹ Su C....Zhou C. (2011)
785. The occurrence of germline BRCA1 and BRCA2 sequence a lterations in Slovenian population. (PubMed id 21232165)¹ Stegel V....NovakoviA8 S. (2011)
786. Regulated recruitment of tumor suppressor BRCA1 to th e p21 gene by coactivator methylation. (PubMed id 21245169)¹ Lee Y.H....Stallcup M.R. (2011)
787. Mutation of a single allele of the cancer susceptibil ity gene BRCA1 leads to genomic instability in human breast epithelial cells. (PubMed id 21987798)¹ Konishi H....Park B.H. (2011)
788. Epigenetic silencing of BRCA1 gene associated with dem ographic and pathologic factors in sporadic breast cancer: a study of an Indian population. (PubMed id 21572332)¹ Singh A.K....Pandey H.P. (2011)
789. System-wide temporal characterization of the proteome and phosphoproteome of human embryonic stem cell differentiation. (PubMed id 21406692)² Rigbolt K.T....Blagoev B. (2011)
790. BRCA1 is required for postreplication repair after UV -induced DNA damage. (PubMed id 21963239)¹ Pathania S....Livingston D.M. (2011)
791. BRCA1-related gene signature in breast cancer: the ro le of ER status and molecular type. (PubMed id 21196292)¹ Lisowska K.M....Jarzab B. (2011)
792. Impact of BRCA1 BRCT domain missense substitutions on phosphopeptide recognition. (PubMed id 21473589)¹ Coquelle N....Glover J.N. (2011)
793. Prevalence of BRCA1 and BRCA2 mutations in triple neg ative breast cancer. (PubMed id 21653198)¹ Evans D.G....Eccles D.M. (2011)
794. Quantitative proteomic identification of the BRCA1 ubi quitination substrates. (PubMed id 21950761)¹ Song M....Shiio Y. (2011)
795. A structural bioinformatics approach to explore the i nteractions of P53 and BRCA1 gene products on ovarian and breast cancer. (PubMed id 21441093)¹ Parija S. and Kumar A. (2011)
796. Loss of BRCA1 leads to an increase in epidermal growth factor receptor expression in mammary epithelial cells, and epidermal growth fa ctor receptor inhibition prevents estrogen receptor-negative cancers in BRCA1-mu tant mice. (PubMed id 21396117)¹ Burga L.N....Wulf G.M. (2011)
797. The BRCA1 ubiquitin ligase and homologous recombinati on repair. (PubMed id 21570976)¹ Ohta T....Wu W. (2011)
798. Assessment of rare BRCA1 and BRCA2 variants of unknow n significance using hierarchical modeling. (PubMed id 21520273)¹ Capanu M....Begg C.B. (2011)
799. Two BRCA1/2 founder mutations in Jews of Sephardic or igin. (PubMed id 21063910)¹ Sagi M....Lerer I. (2011)
800. No evidence of excess breast cancer risk among mutati on-negative women from BRCA mutation-positive families. (PubMed id 20458532)¹ Korde L.A....Mai P.L. (2011)
801. Microcephalin is a new novel prognostic indicator in breast cancer associated with BRCA1 inactivation. (PubMed id 20632086)¹ Richardson J....Bell S.M. (2011)
802. CpG island hypermethylation of BRCA1 and loss of pRb as co-occurring events in basal/triple-negative breast cancer. (PubMed id 21593597)¹ Stefansson O.A....Eyfjord J.E. (2011)
803. BRCA1 mutations do not increase prostate cancer risk: results from a meta-analysis including new data. (PubMed id 21520156)¹ Fachal L....Vega A. (2011)
804. BRCA1 is an essential regulator of heart function and survival following myocardial infarction. (PubMed id 22186889)¹ Shukla P.C....Verma S. (2011)
805. A high prevalence of BRCA1 mutations among breast can cer patients from the Bahamas. (PubMed id 20838878)¹ Donenberg T....Hurley J. (2011)
806. Detection of BRCA1 and BRCA2 gene mutation in Egyptian females with breast cancer and their relatives by PCR-SSCP method. (PubMed id 23082475)¹ Fattouh M....Hafez E.e.l.-.S. (2011)
807. A de novo complete BRCA1 gene deletion identified in a Spanish woman with early bilateral breast cancer. (PubMed id 21989022)¹ Garcia-Casado Z....Lopez-Guerrero J.A. (2011)
808. Splicing and multifactorial analysis of intronic BRCA 1 and BRCA2 sequence variants identifies clinically significant splicing aberra tions up to 12 nucleotides from the intron/exon boundary. (PubMed id 21394826)¹ Whiley P.J....Spurdle A.B. (2011)
809. Multifunctional transcription factor TFII-I is an act ivator of BRCA1 function. (PubMed id 21407215)¹ Tanikawa M....Taketani Y. (2011)
810. NBA1/MERIT40 and BRE interaction is required for the integrity of two distinct deubiquitinating enzyme BRCC36-containing complexes. (PubMed id 21282113)¹ Hu X....Wang B. (2011)
811. Assessment of the prevalence of de novo mutations in the BRCA1 and BRCA2 genes. (PubMed id 21649643)¹ Zhang L....Robson M.E. (2011)
812. Tumor suppressor BRCA1 epigenetically controls oncoge nic microRNA-155. (PubMed id 21946536)¹ Chang S....Sharan S.K. (2011)
813. Genetic variation in IGF2 and HTRA1 and breast cancer risk among BRCA1 and BRCA2 carriers. (PubMed id 21708937)¹ Neuhausen S.L....Gillen D.L. (2011)
814. Prophylactic and therapeutic mastectomy in BRCA mutat ion carriers: can the nipple be preserved? (PubMed id 21947588)¹ Reynolds C....Boughey J.C. (2011)
815. A recombination-based method to characterize human BR CA1 missense variants. (PubMed id 20737206)¹ Guidugli L....Caligo M.A. (2011)
816. Personalizing cancer treatment in the age of global g enomic analyses: PALB2 gene mutations and the response to DNA damaging agents i n pancreatic cancer. (PubMed id 21135251)¹ Villarroel M.C....Hidalgo M. (2011)
817. Systematic and quantitative assessment of the ubiquiti n-modified proteome. (PubMed id 21906983)¹ Kim W....Gygi S.P. (2011)
818. Down-regulation of BRCA1 expression by miR-146a and m iR-146b-5p in triple negative sporadic breast cancers. (PubMed id 21472990)¹ Garcia A.I....Mazoyer S. (2011)
819. [The correlation between chemotherapeutic efficacy and breast cancer susceptibility gene 1 and class IIIb-tubulin protein expression i n non-small cell lung cancer patients]. (PubMed id 21781528)¹ Wan Y.Y....Wu J. (2011)
820. Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia. (PubMed id 22032251)¹ Plakhins G....Gardovskis J. (2011)
821. A novel de novo BRCA1 mutation in a Chinese woman wit h early onset breast cancer. (PubMed id 21404118)¹ Kwong A....Ford J.M. (2011)
822. BRCA1 tumour suppression occurs via heterochromatin-m ediated silencing. (PubMed id 21901007)¹ Zhu Q....Verma I.M. (2011)
823. Genomic large rearrangement screening of BRCA1 and BR CA2 genes in high-risk Turkish breast/ovarian cancer patients by using multiple x ligation-dependent probe amplification assay. (PubMed id 20919953)¹ ManguoA9lu E....LA1leci G. (2011)
824. Modification of BRCA1-Associated Breast and Ovarian C ancer Risk by BRCA1-Interacting Genes. (PubMed id 21799032)¹ Rebbeck T.R....Nathanson K.L. (2011)
825. MDC1 is ubiquitylated on its tandem BRCT domain and d irectly binds RAP80 in a UBC13-dependent manner. (PubMed id 21622030)¹ Strauss C....Goldberg M. (2011)
826. Prediction of single-nucleotide substitutions that re sult in exon skipping: identification of a splicing silencer in BRCA1 exon 6. (PubMed id 21309043)¹ Raponi M....Vorechovsky I. (2011)
827. Identifying the effects of BRCA1 mutations on homologo us recombination using cells that express endogenous wild-type BRCA1. (PubMed id 21372787)¹ Parvin J....Ransburgh D. (2011)
828. The impact of contralateral mastectomy on mortality i n BRCA1 and BRCA2 mutation carriers with breast cancer. (PubMed id 21455666)¹ Narod S.A. (2011)
829. Synthetic lethality of PARP inhibition in cancers lac king BRCA1 and BRCA2 mutations. (PubMed id 21487248)¹ Dedes K.J....Reis-Filho J.S. (2011)
830. Association of Rad51 polymorphism with DNA repair in BRCA1 mutation carriers and sporadic breast cancer risk. (PubMed id 21708019)¹ Ricks-Santi L.J....Shields P.G. (2011)
831. Profiling of the BRCA1 transcriptome through microarra y and ChIP-chip analysis. (PubMed id 21880590)¹ Gorski J.J....Harkin D.P. (2011)
832. On the origin and diffusion of BRCA1 c.5266dupC (5382 insC) in European populations. (PubMed id 21119707)¹ Hamel N....Foulkes W.D. (2011)
833. A 67-year-old woman with BRCA 1 mutation associated w ith pancreatic adenocarcinoma. (PubMed id 20711688)¹ Lowery M....O'Reilly E.M. (2011)
834. RAP80-directed tuning of BRCA1 homologous recombinati on function at ionizing radiation-induced nuclear foci. (PubMed id 21406551)¹ Hu Y....Livingston D.M. (2011)
835. Cancer worry among Norwegian male BRCA1/2 mutation ca rriers. (PubMed id 21603983)¹ StrA...Gjengedal E. (2011)
836. c-Myc activates BRCA1 gene expression through distal promoter elements in breast cancer cells. (PubMed id 21668996)¹ Chen Y....Olopade O.I. (2011)
837. Two novel variants in the 3'UTR of the BRCA1 gene in familial breast and/or ovarian cancer. (PubMed id 20848184)¹ Lheureux S....Hardouin A. (2011)
838. BRCA1 and BRCA2 germline mutations in Uruguayan breas t and breast-ovarian cancer families. Identification of novel mutations and unc lassified variants. (PubMed id 21190077)¹ Delgado L....Muse I.M. (2011)
839. Breast cancer 1 (BRCA1) protein expression as a progn ostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correl ative study. (PubMed id 21368065)¹ Weberpals J.I....Eisenhauer E.A. (2011)
840. Mutations in the BRCT binding site of BRCA1 result in hyper-recombination. (PubMed id 21666281)¹ Dever S.M....Valerie K. (2011)
841. An exploration of the communication preferences regar ding genetic testing in individuals from families with identified breast/ovaria n cancer mutations. (PubMed id 20878485)¹ Ratnayake P....Tucker K. (2011)
842. Correlation of BRCA1, TXR1 and TSP1 mRNA expression w ith treatment outcome to docetaxel-based first-line chemotherapy in patients wi th advanced/metastatic non-small-cell lung cancer. (PubMed id 21157449)¹ Papadaki C....Souglakos J. (2011)
843. Coexpression of the mutated BRCA1 mRNA and p53 mRNA a nd its association in Chinese prostate cancer. (PubMed id 19269198)¹ Ding G.F....Zhao H.P. (2011)
844. Characteristics of triple-negative breast cancer in p atients with a BRCA1 mutation: results from a population-based study of young w omen. (PubMed id 22010008)¹ Lee E....Ursin G. (2011)
845. Cordycepin blocks lung injury-associated inflammation and promotes BRCA1-deficient breast cancer cell killing by effectively inhibitin g PARP. (PubMed id 21607289)¹ Kim H....Boulares A.H. (2011)
846. Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. (PubMed id 21427728)¹ Osorio A....BenA-tez J. (2011)
847. Allelic imbalance in BRCA1 and BRCA2 gene expression and familial ovarian cancer. (PubMed id 21119070)¹ Shen J....Zhao H. (2011)
848. Evolutionary dynamics of BRCA1 alterations in breast tumorigenesis. (PubMed id 21194536)¹ De Vargas Roditi L. and Michor F. (2011)
849. Development of breast cancer in a 21-year-old childho od Wilms' tumor survivor with a BRCA1 2634delC mutation. (PubMed id 21729660)¹ Dulude A.M....Ramanathan R.K. (2011)
850. [EGFR gene copy number, ERCC1 and BRCA1 protein expres sion and their relationship in non-small cell lung cancer]. (PubMed id 22093627)¹ Deng Q.H....He J.X. (2011)
851. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative br east cancer patients. (PubMed id 21135055)¹ Vollebergh M.A....Linn S.C. (2011)
852. BRCA1/2 status and clinicopathologic characteristics of patients with double primary breast and ovarian cancer. (PubMed id 21391735)¹ Cvelbar M....Teugels E. (2011)
853. Variation in the BRCA2 gene in a child with medullobl astoma and a family history of breast cancer. (PubMed id 22044372)¹ Bayrakli F....Gurelik M. (2011)
854. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. (PubMed id 21324516)¹ Zhang S....Narod S.A. (2011)
855. Nanoparticle-mediated delivery of siRNA targeting Par p1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells. (PubMed id 21187397)¹ Goldberg M.S....Sharp P.A. (2011)
856. Histone methyltransferase EZH2 induces Akt-dependent genomic instability and BRCA1 inhibition in breast cancer. (PubMed id 21406404)¹ Gonzalez M.E....Kleer C.G. (2011)
857. Expression of excision repair cross-complementation g roup 1, breast cancer susceptibility 1, and I^ III-tubulin in thymic epithelial tumors. (PubMed id 21289518)¹ Kaira K....Yamamoto N. (2011)
858. BRCA1 contributes to transcription-coupled repair of DNA damage through polyubiquitination and degradation of Cockayne syndrome B pr otein. (PubMed id 21756275)¹ Wei L....Chiba N. (2011)
859. Improved survival in non-Ashkenazi Jewish ovarian can cer patients with BRCA1 and BRCA2 gene mutations. (PubMed id 21276604)¹ Lacour R.A....Lu K.H. (2011)
860. Human epidermal growth factor receptor 2, Na+/H+ exch anger regulatory factor 1, and breast cancer susceptibility gene-1 as new bioma rkers for familial breast cancers. (PubMed id 21496870)¹ Mangia A....Paradiso A. (2011)
861. Identification of novel intronic BRCA1 variants of un certain significance in a Thai hereditary breast cancer family. (PubMed id 21869484)¹ Ratanaphan A....Maipang T. (2011)
862. Genomic signature of BRCA1 deficiency in sporadic bas al-like breast tumors. (PubMed id 21104783)¹ Joosse S.A....Nederlof P.M. (2011)
863. BRCA1 RING function is essential for tumor suppressio n but dispensable for therapy resistance. (PubMed id 22172724)¹ Drost R....Jonkers J. (2011)
864. Common variants of the BRCA1 wild-type allele modify t he risk of breast cancer in BRCA1 mutation carriers. (PubMed id 21890493)¹ Cox D.G....Sinilnikova O.M. (2011)
865. Germline mutations in BRCA1 and BRCA2 genes in ethnic ally diverse high risk families in Israel. (PubMed id 20960228)¹ Laitman Y....Friedman E. (2011)
866. Targeted prostate cancer screening in men with mutati ons in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. (PubMed id 20840664)¹ Mitra A.V....Eeles R.A. (2011)
867. Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. (PubMed id 20644999)¹ Grann V.R....Neugut A.I. (2011)
868. p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage. (PubMed id 21742769)¹ Jiang J....Xia F. (2011)
869. An emerging entity: pancreatic adenocarcinoma associat ed with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. (PubMed id 21934105)¹ Lowery M.A....O'Reilly E.M. (2011)
870. Bcl-2 inhibits nuclear homologous recombination by lo calizing BRCA1 to the endomembranes. (PubMed id 21444675)¹ Laulier C....Lopez B.S. (2011)
871. BRCA1 counteracts progesterone action by ubiquitinati on leading to progesterone receptor degradation and epigenetic silencing of tar get promoters. (PubMed id 21531767)¹ Calvo V. and Beato M. (2011)
872. Loss of BRCA1 protein expression as indicator of the B RCAness phenotype is associated with favorable overall survival after complete r esection of sporadic ovarian cancer. (PubMed id 21897273)¹ Radosa M.P....Runnebaum I.B. (2011)
873. The prostaglandin transporter regulates adipogenesis a nd aromatase transcription. (PubMed id 21212407)¹ Subbaramaiah K....Dannenberg A.J. (2011)
874. Association of BRCA1 and BRCA2 mutations with surviva l, chemotherapy sensitivity, and gene mutator phenotype in patients with ovaria n cancer. (PubMed id 21990299)¹ Yang D....Zhang W. (2011)
875. Cell cycle-dependent conjugation of endogenous BRCA1 protein with SUMO-2/3. (PubMed id 21147198)¹ Vialter A....Rio P.G. (2011)
876. E3 ligases determine ubiquitination site and conjugat e type by enforcing specificity on E2 enzymes. (PubMed id 21965653)¹ David Y....Navon A. (2011)
877. Common breast cancer susceptibility alleles are associ ated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. (PubMed id 22053997)¹ Mulligan A.M.... . (2011)
878. Genetic polymorphisms in AURKA and BRCA1 are associat ed with breast cancer susceptibility in a Chinese Han population. (PubMed id 21598251)¹ Ruan Y....Fang W.G. (2011)
879. Involvement of MyoD and c-myb in regulation of basal and estrogen-induced transcription activity of the BRCA1 gene. (PubMed id 20364308)¹ Jin W....Shao Z.M. (2011)
880. Microscopic and early-stage ovarian cancers in BRCA1/ 2 mutation carriers: building a model for early BRCA-associated tumorigenesis. (PubMed id 21278312)¹ Yates M.S....Lu K.H. (2011)
881. Comparative proteomic analysis identifies a role for S UMO in protein quality control. (PubMed id 21693764)¹ Tatham M.H....Hay R.T. (2011)
882. Common alleles at 6q25.1 and 1p11.2 are associated wi th breast cancer risk for BRCA1 and BRCA2 mutation carriers. (PubMed id 21593217)¹ Antoniou A.C....Chenevix-Trench G. (2011)
883. Cancer risk in Jewish BRCA1 and BRCA2 mutation carrier s: effects of oral contraceptive use and parental origin of mutation. (PubMed id 21499684)¹ Bernholtz S....Friedman E. (2011)
884. Breast cancer surgery trend changes since the introdu ction of BRCA1/2 mutation screening: a retrospective cohort analysis of 158 mut ation carriers treated at a single institution. (PubMed id 20972632)¹ Mislowsky A....Tchou J. (2011)
885. Alcohol metabolism in human cells causes DNA damage an d activates the Fanconi anemia-breast cancer susceptibility (FA-BRCA) DNA damage response network. (PubMed id 21919919)¹ Abraham J....Brooks P.J. (2011)
886. BRCA1 is both a prognostic and predictive biomarker o f response to chemotherapy in sporadic epithelial ovarian cancer. (PubMed id 21920589)¹ Carser J.E....Harkin D.P. (2011)
887. Cdk1 and BRCA1 target I^-tubulin to microtubule domain s. (PubMed id 21951856)¹ Hubert T....Gettemans J. (2011)
888. Variation in breast cancer risk with mutation position , smoking, alcohol, and chest X-ray history, in the French National BRCA1/2 carr ier cohort (GENEPSO). (PubMed id 21761160)¹ Lecarpentier J....Andrieu N. (2011)
889. The BRCA1-RAP80 complex regulates DNA repair mechanis m utilization by restricting end resection. (PubMed id 21335604)¹ Coleman K.A. and Greenberg R.A. (2011)
890. Mechanisms of increased risk of tumorigenesis in Atm a nd Brca1 double heterozygosity. (PubMed id 21849032)¹ Wang J....Zhou G. (2011)
891. Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. (PubMed id 19996031)¹ Kurian A.W....Plevritis S.K. (2010)
892. Functional variant of KLOTHO: a breast cancer risk mo difier among BRCA1 mutation carriers of Ashkenazi origin. (PubMed id 19802015)¹ Wolf I....Kaufman B. (2010)
893. Large BRCA1 and BRCA2 genomic rearrangements in Malay sian high risk breast-ovarian cancer families. (PubMed id 20617377)¹ Kang P....Teo S.H. (2010)
894. PI 3 kinase related kinases-independent proteolysis o f BRCA1 regulates Rad51 recruitment during genotoxic stress in human cells. (PubMed id 21103343)¹ Hammond-Martel I....Affar e.l. .B. (2010)
895. Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the l iterature. (PubMed id 20033769)¹ Kirova Y.M....Fourquet A. (2010)
896. Ionizing radiation or mitomycin-induced micronuclei i n lymphocytes of BRCA1 or BRCA2 mutation carriers. (PubMed id 20625817)¹ GutiAcrrez-EnrA-quez S....Diez O. (2010)
897. High frequency and allele-specific differences of BRC A1 founder mutations in breast cancer and ovarian cancer patients from Belarus. (PubMed id 20569256)¹ Bogdanova N.V....DAPrk T. (2010)
898. Long-term outcomes of breast cancer in women aged 30 years or younger, based on family history, pathology and BRCA1/BRCA2/TP53 statu s. (PubMed id 20234365)¹ Evans D.G....Lalloo F. (2010)
899. DNA damage-induced cytotoxicity is dissociated from B RCA1's DNA repair function but is dependent on its cytosolic accumulation. (PubMed id 20631074)¹ Wang H....Xia F. (2010)
900. Validation of the pedigree assessment tool (PAT) in f amilies with BRCA1 and BRCA2 mutations. (PubMed id 19763692)¹ Teller P....Gabram S.G. (2010)
901. BRCA1 and XRCC1 polymorphisms associated with surviva l in advanced gastric cancer treated with taxane and cisplatin. (PubMed id 20331623)¹ Shim H.J....Chung I.J. (2010)
902. Genomic alterations in histopathologically normal bre ast tissue from BRCA1 mutation carriers may be caused by BRCA1 haploinsufficien cy. (PubMed id 19839046)¹ Rennstam K....Hedenfalk I. (2010)
903. The CASP8 rs3834129 polymorphism and breast cancer ri sk in BRCA1 mutation carriers. (PubMed id 20652397)¹ Catucci I....Peterlongo P. (2010)
904. BRCA1: linking HOX to breast cancer suppression. (PubMed id 20727230)¹ Jin K. and Sukumar S. (2010)
905. Comparing the frequency of common genetic variants an d haplotypes between carriers and non-carriers of BRCA1 and BRCA2 deleterious m utations in Australian women diagnosed with breast cancer before 40 years of ag e. (PubMed id 20807450)¹ Turkovic L....Hopper J.L. (2010)
906. Effect of genetic counseling and testing for BRCA1 an d BRCA2 mutations in African American women: a randomized trial. (PubMed id 20234119)¹ Halbert C.H....Domchek S. (2010)
907. Comprehensive analysis of DNA repair gene polymorphis ms and survival in patients with early stage non-small-cell lung cancer. (PubMed id 20731661)¹ Kim M....Park J.Y. (2010)
908. [No association between MTHFR 677C>T polymorphism and ovarian cancer risk in BRCA1 mutation carriers in Wielkopolska region]. (PubMed id 20825051)¹ Magnowski P....SpaczyA8ski M. (2010)
909. BRCA1-associated breast and ovarian cancer risks in P oland: no association with commonly studied polymorphisms. (PubMed id 19360465)¹ Jakubowska A....Hamann U. (2010)
910. Transcriptional regulation of the base excision repai r pathway by BRCA1. (PubMed id 20185827)¹ Saha T....Rosen E.M. (2010)
911. Association of the variants CASP8 D302H and CASP10 V4 10I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. (PubMed id 20978178)¹ Engel C....Schmutzler R.K. (2010)
912. The rate of the predominant Jewish mutations in the B RCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patien ts. (PubMed id 20850175)¹ Barak F....Friedman E. (2010)
913. Prioritizing candidate genetic modifiers of BRCA1 and BRCA2 using a combinatorial analysis of global expression and polymorphism ass ociation studies of breast cancer. (PubMed id 20721735)¹ Walker L.C. and Spurdle A.B. (2010)
914. Adjuvant systemic therapy for breast cancer in BRCA1/ BRCA2 mutation carriers in a population-based study of risk of contralateral br east cancer. (PubMed id 20135344)¹ Reding K.W....Malone K.E. (2010)
915. The CYP17A1 -34T > C polymorphism and breast cance r risk in BRCA1 and BRCA2 mutation carriers. (PubMed id 20798986)¹ Kaufman B....Friedman E. (2010)
916. BRCA1 and BRCA2 families and the risk of skin cancer. (PubMed id 20809262)¹ Ginsburg O.M....Narod S.A. (2010)
917. Genetic variation in genes interacting with BRCA1/2 a nd risk of breast cancer in the Cypriot population. (PubMed id 19714462)¹ Loizidou M.A....Kyriacou K. (2010)
918. Enhanced mismatch mutation analysis: simultaneous det ection of point mutations and large scale rearrangements by capillary electroph oresis, application to BRCA1 and BRCA2. (PubMed id 20721742)¹ Houdayer C....Stoppa-Lyonnet D. (2010)
919. Prevalence of BRCA2 and CDKN2a mutations in German fa milial pancreatic cancer families. (PubMed id 20195775)¹ Slater E.P....Bartsch D.K. (2010)
920. Sleep disturbances in asymptomatic BRCA1/2 mutation c arriers: women at high risk for breast-ovarian cancer. (PubMed id 20337906)¹ Shochat T. and Dagan E. (2010)
921. Osteopontin can act as an effector for a germline mut ation of BRCA1 in malignant transformation of breast cancer-related cells. (PubMed id 20384635)¹ El-Tanani M.K....Rudland P.S. (2010)
922. Wild-type BRCA1, but not mutated BRCA1, regulates the expression of the nuclear form of beta-catenin. (PubMed id 20215423)¹ Li H....Avraham H.K. (2010)
923. Effect of BRCA1/2 mutation on short-term and long-ter m breast cancer survival: a systematic review and meta-analysis. (PubMed id 20376556)¹ Lee E.H.... . (2010)
924. Structure of the DNA-bound BRCA1 C-terminal region fr om human replication factor C p140 and model of the protein-DNA complex. (PubMed id 20081198)¹ Kobayashi M....Siegal G. (2010)
925. Contribution of CDKN2A/P16 ( INK4A ), P14 (ARF), CDK4 and BRCA1/2 germline mutations in individuals with suspected genetic predispos ition to uveal melanoma. (PubMed id 20842456)¹ Buecher B....Stoppa-Lyonnet D. (2010)
926. Body weight and risk of breast cancer in BRCA1/2 muta tion carriers. (PubMed id 20730487)¹ Manders P....Rookus M.A. (2010)
927. BRCA1/2 test results impact risk management attitudes , intentions, and uptake. (PubMed id 20383578)¹ O'Neill S.C....Schwartz M.D. (2010)
928. MRG15 binds directly to PALB2 and stimulates homology -directed repair of chromosomal breaks. (PubMed id 20332121)¹ Hayakawa T....Andreassen P.R. (2010)
929. Risk factors for carcinoma of the fallopian tube in w omen with and without a germline BRCA mutation. (PubMed id 20452659)¹ Vicus D....Narod S.A. (2010)
930. Common variants associated with breast cancer in geno me-wide association studies are modifiers of breast cancer risk in BRCA1 and BR CA2 mutation carriers. (PubMed id 20418484)¹ Wang X....Couch F.J. (2010)
931. Impact of RING and BRCT domain mutations on BRCA1 pro tein stability, localization and recruitment to DNA damage. (PubMed id 20681793)¹ Nelson A.C. and Holt J.T. (2010)
932. Developing functional assays for BRCA1 unclassified v ariants. (PubMed id 20721750)¹ Webb M. (2010)
933. Methylation of the tumor suppressor protein, BRCA1, i nfluences its transcriptional cofactor function. (PubMed id 20614009)¹ Guendel I....Kehn-Hall K. (2010)
934. Expression of the stem cell marker ALDH1 in the norma l breast of BRCA1 mutation carriers. (PubMed id 20585849)¹ Heerma van Voss M.R....van Diest P.J. (2010)
935. Quantitative phosphoproteomics reveals widespread full phosphorylation site occupancy during mitosis. (PubMed id 20068231)² Olsen J.V....Mann M. (2010)
936. Identification of DBC1 as a transcriptional repressor for BRCA1. (PubMed id 20160719)¹ Hiraike H....Taketani Y. (2010)
937. Population-based study of BRCA1/2 mutations: family h istory based criteria identify minority of mutation carriers. (PubMed id 20353281)¹ Mateju M....Pohlreich P. (2010)
938. Identification of a preneoplastic gene expression pro file in tubal epithelium of BRCA1 mutation carriers. (PubMed id 21170264)¹ Press J.Z....Swisher E.M. (2010)
939. Germline mutations of BRCA1 and BRCA2 genes in Turkis h breast, ovarian, and prostate cancer patients. (PubMed id 21156238)¹ ManguoA9lu E....LA1leci G. (2010)
940. Complete BRCA mutation screening in breast and ovaria n cancer predisposition families from a North-Eastern Romanian population. (PubMed id 20567915)¹ Negura L....Bignon Y.J. (2010)
941. Screening for genomic rearrangements in BRCA1 and BRC A2 genes in Czech high-risk breast/ovarian cancer patients: high proportion of population specific alterations in BRCA1 gene. (PubMed id 20135348)¹ Ticha I....Pohlreich P. (2010)
942. Turnover of BRCA1 involves in radiation-induced apopt osis. (PubMed id 21217819)¹ Liu W....Wan Y. (2010)
943. Alterations in p53, BRCA1, ATM, PIK3CA, and HER2 gene s and their effect in modifying clinicopathological characteristics and overall survival of Bulgarian patients with breast cancer. (PubMed id 20177704)¹ Bozhanov S.S....Georgieva E.I. (2010)
944. Evaluation of established breast cancer risk factors as modifiers of BRCA1 or BRCA2: a multi-center case-only analysis. (PubMed id 20309627)¹ Moorman P.G....Schildkraut J.M. (2010)
945. Identification of point mutations and large rearrange ments in the BRCA1 gene in 667 Turkish unselected ovarian cancer patients. (PubMed id 20638108)¹ Aktas D....Ayhan A. (2010)
946. Cloning and characterization of a new BRCA1 variant: A role for BRCT domains in apoptosis. (PubMed id 20356671)¹ Gu M.... Zheng C. (2010)
947. AKT1/BRCA1 in the control of homologous recombination and genetic stability: the missing link between hereditary and sporadic breast cancers. (PubMed id 21321378)¹ Guirouilh-Barbat J.K....Lopez B.S. (2010)
948. Identification of novel large genomic rearrangements at the BRCA1 locus in Malaysian women with breast cancer. (PubMed id 20451485)¹ Sharifah N.A....Nor Hisham A. (2010)
949. Increased chromosomal radiosensitivity in women carry ing BRCA1/BRCA2 mutations assessed with the G2 assay. (PubMed id 20206018)¹ Ernestos B....Michael K. (2010)
950. Searching for large genomic rearrangements of the BRC A1 gene in a Nigerian population. (PubMed id 20596889)¹ Zhang J....Olopade O.I. (2010)
951. Characterization of BRCA1 ring finger variants of unc ertain significance. (PubMed id 19543972)¹ Sweet K....Toland A.E. (2010)
952. HERC2 is an E3 ligase that targets BRCA1 for degradat ion. (PubMed id 20631078)¹ Wu W....Ohta T. (2010)
953. Cancer prevalence in 129 breast-ovarian cancer famili es tested for BRCA1 and BRCA2 mutations. (PubMed id 20459916)¹ Schlebusch C.M....van Rensburg E.J. (2010)
954. Gross genomic alterations and gene expression profile s of high- grade serous carcinoma of the ovary with and without BRCA1 inactivat ion. (PubMed id 20843305)¹ Pradhan M....Lee C.H. (2010)
955. BRCA1 16 years later: nuclear import and export proce sses. (PubMed id 20608972)¹ Thompson M.E. (2010)
956. Identification and Management of Women With BRCA Muta tions or Hereditary Predisposition for Breast and Ovarian Cancer. (PubMed id 21123638)¹ Pruthi S....Lindor N.M. (2010)
957. Expression of TRF1, TRF2, TIN2, TERT, KU70, and BRCA1 proteins is associated with telomere shortening and may contribute to multista ge carcinogenesis of gastric cancer. (PubMed id 20127252)¹ Hu H....Liang X.Q. (2010)
958. Identification and functional analysis of novel BRCA1 transcripts, including mouse Brca1-Iris and human pseudo-BRCA1. (PubMed id 19067158)¹ Pettigrew C.A....Brown M.A. (2010)
959. Gamma-radiation sensitivity and polymorphisms in RAD5 1L1 modulate glioma risk. (PubMed id 20610542)¹ Liu Y....Bondy M.L. (2010)
960. Sporadic breast carcinomas with somatic BRCA1 gene de letions share genotype/phenotype features with familial breast carcinomas. (PubMed id 20944121)¹ Rhiem K....Schmutzler R.K. (2010)
961. Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays. (PubMed id 20516115)¹ Lee M.S....Glover J.N. (2010)
962. [BRCA1 selectively regulates the expression of proges terone receptor A in sporadic invasive ductal breast carcinoma]. (PubMed id 20646629)¹ Wang X....Xiong J.B. (2010)
963. BRCA1 and BRCA2 germline mutations screening in Alger ian breast/ovarian cancer families. (PubMed id 20683152)¹ Cherbal F....Maillet P. (2010)
964. Increased incidence of visceral metastases in scottis h patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian B RCAness phenotype. (PubMed id 20406939)¹ Gourley C....Ferguson M. (2010)
965. Variation within DNA repair pathway genes and risk of multiple sclerosis. (PubMed id 20522537)¹ Briggs F.B....Barcellos L.F. (2010)
966. Is mammographic breast density a breast cancer risk f actor in women with BRCA mutations? (PubMed id 20625126)¹ Passaperuma K....Yaffe M.J. (2010)
967. Oral poly(ADP-ribose) polymerase inhibitor olaparib i n patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof- of-concept trial. (PubMed id 20609468)¹ Audeh M.W....Tutt A. (2010)
968. Prophylactic mastectomy in BRCA1 and BRCA2 mutation c arriers: very low risk for subsequent breast cancer. (PubMed id 20134318)¹ Kaas R....Rutgers E.J. (2010)
969. Expanding the criteria for BRCA mutation testing in b reast cancer survivors. (PubMed id 20733129)¹ Kwon J.S....Arun B. (2010)
970. Association between mitogen-activated protein kinase kinase kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59, 977 subjects. (PubMed id 20809358)¹ Lu P.H....Tao G.Q. (2010)
971. Heterogeneous prevalence of recurrent BRCA1 and BRCA2 mutations in Spain according to the geographical area: implications for geneti c testing. (PubMed id 19941167)¹ Diez O....BalmaA+a J. (2010)
972. Breast cancer risks in individuals testing negative f or a known family mutation in BRCA1 or BRCA2. (PubMed id 19885732)¹ Domchek S.M....Robson M. (2010)
973. Genetic susceptibility to distinct bladder cancer sub phenotypes. (PubMed id 19692168)¹ Guey L.T....Malats N. (2010)
974. Family history, BRCA mutations and breast cancer in V ietnamese women. (PubMed id 20950396)¹ Ginsburg O....Narod S. (2010)
975. Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma pa tients. (PubMed id 20470789)¹ Sharma G....Ralhan R. (2010)
976. [Genes beyond BRCA1 and BRCA2 for hereditary breast c ancer]. (PubMed id 20890790)¹ Simon K....Pristauz G. (2010)
977. The contribution of founder mutations in BRCA1 to bre ast cancer in Belarus. (PubMed id 20507347)¹ Uglanitsa N....Gronwald J. (2010)
978. BRCA1-associated epigenetic regulation of p73 mediate s an effector pathway for chemosensitivity in ovarian carcinoma. (PubMed id 20807817)¹ Ibrahim N....Ellisen L.W. (2010)
979. Oral contraceptive use and breast or ovarian cancer r isk in BRCA1/2 carriers: a meta-analysis. (PubMed id 20537530)¹ Iodice S....Gandini S. (2010)
980. The contribution of founder mutations in BRCA1 to bre ast and ovarian cancer in Lithuania. (PubMed id 20345474)¹ Elsakov P....Gronwald J. (2010)
981. A Large-scale genetic association study of esophageal adenocarcinoma risk. (PubMed id 20453000)¹ Liu C.Y....Christiani D.C. (2010)
982. Association of BRCA1 mutations with occult primary ov arian insufficiency: a possible explanation for the link between infertility an d breast/ovarian cancer risks. (PubMed id 19996028)¹ Oktay K....Babayev S.N. (2010)
983. The c.5242C>A BRCA1 missense variant induces exon skipping by increasing splicing repressors binding. (PubMed id 19404736)¹ Millevoi S....Toulas C. (2010)
984. Spectrum of BRCA1/2 point mutations and genomic rearr angements in high-risk breast/ovarian cancer Chilean families. (PubMed id 20859677)¹ Gonzalez-Hormazabal P....Jara L. (2010)
985. Can a phenotype for recessive inheritance in breast c ancer be defined? (PubMed id 20549370)¹ Ellberg C....Olsson H. (2010)
986. Identification of a novel mutations BRCA1*c.80 + 3del 4 and BRCA2*c.6589delA in Slovak HBOC families. (PubMed id 19011960)¹ Konecny M....Weismanova E. (2010)
987. Risk of breast cancer in male BRCA2 carriers. (PubMed id 20587410)¹ Evans D.G....Lalloo F. (2010)
988. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. (PubMed id 20379614)¹ Rose J.E....Uhl G.R. (2010)
989. BRCA1 185delAG mutant protein, BRAt, up-regulates mas pin in ovarian epithelial cells. (PubMed id 19906413)¹ O'Donnell J.D....Kruk P.A. (2010)
990. Risk factors associated with the occurrence of breast cancer after bilateral salpingo-oophorectomy in high-risk women. (PubMed id 20638925)¹ Ramon Y Cajal T....Barnadas A. (2010)
991. BRCA1, BRCA2 and CHEK2 c.1100 delC mutations in patie nts with double primaries of the breasts and/or ovaries. (PubMed id 20472656)¹ Evans D.G....Wallace A. (2010)
992. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors i n ovarian cancer. (PubMed id 20606085)¹ Hennessy B.T....Mills G.B. (2010)
993. Bayes analysis provides evidence of pathogenicity for the BRCA1 c.135-1G>T (IVS3-1) and BRCA2 c.7977-1G>C (IVS17-1) variants d isplaying in vitro splicing results of equivocal clinical significance. (PubMed id 20020529)¹ Spurdle A.B....Goldgar D.E. (2010)
994. BRCA germline mutations in women with uterine serous carcinoma--still a debate. (PubMed id 21119368)¹ Lavie O....Gemer O. (2010)
995. Alcohol consumption and the risk of breast cancer amo ng BRCA1 and BRCA2 mutation carriers. (PubMed id 20541936)¹ Dennis J....Narod S. (2010)
996. Prevalence of the variant allele rs61764370 T>G in the 3'UTR of KRAS among Dutch BRCA1, BRCA2 and non-BRCA1/BRCA2 breast cancer f amilies. (PubMed id 20676756)¹ Hollestelle A....Weidhaas J.B. (2010)
997. Impact of BRCA mutations on female fertility and offs pring sex ratio. (PubMed id 19642207)¹ Moslehi R....Friedman J.M. (2010)
998. Four new cases of double heterozygosity for BRCA1 and BRCA2 gene mutations: clinical, pathological, and family characteristics. (PubMed id 20373018)¹ Zuradelli M....Radice P. (2010)
999. BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications. (PubMed id 20608970)¹ Linger R.J. and Kruk P.A. (2010)
1000. Local therapy in BRCA1 and BRCA2 mutation carriers wi th operable breast cancer: comparison of breast conservation and mastectomy. (PubMed id 20411323)¹ Pierce L.J....Domchek S.M. (2010)
1001. Basal-like breast cancer displays distinct patterns o f promoter methylation. (PubMed id 20505321)¹ Lee J.S....Sukumar S. (2010)
1002. Gene methylation in breast ductal fluid from BRCA1 an d BRCA2 mutation carriers. (PubMed id 20056647)¹ Antill Y.C....Campbell I.G. (2010)
1003. Oral poly(ADP-ribose) polymerase inhibitor olaparib i n patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of -concept trial. (PubMed id 20609467)¹ Tutt A....Carmichael J. (2010)
1004. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families. (PubMed id 20221693)¹ Stadler Z.K....Robson M.E. (2010)
1005. BRCA1 represses amphiregulin gene expression. (PubMed id 20103632)¹ Lamber E.P....Parvin J.D. (2010)
1006. BRCA1 modulates the expression of hnRNPA2B1 and KHSRP . (PubMed id 21099359)¹ Santarosa M....Maestro R. (2010)
1007. BRCA1 16 years later: DNA damage-induced BRCA1 shuttl ing. (PubMed id 20608971)¹ Yang E.S. and Xia F. (2010)
1008. Development of a scoring system to screen for BRCA1/2 mutations. (PubMed id 20721747)¹ Evans G.R. and Lalloo F. (2010)
1009. Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers. (PubMed id 21080930)¹ Tung N....Richardson A.L. (2010)
1010. BRCA1-Associated Breast Cancers Present Differently F rom BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study. (PubMed id 21079137)¹ Rijnsburger A.J....Klijn J.G. (2010)
1011. Oral contraceptives and postmenopausal hormones and r isk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study. (PubMed id 19597986)¹ Figueiredo J.C....Bernstein J.L. (2010)
1012. Interaction between BRCA1/BRCA2 and ATM/ATR associate with breast cancer susceptibility in a Chinese Han population. (PubMed id 20513533)¹ Wang K....Song Y. (2010)
1013. Identification of a novel BRCA1 nucleotide 4803delCC/ c.4684delCC mutation and a nucleotide 249T>A/c.130T>A (p.Cys44Ser) mutati on in two Greenlandic Inuit families: implications for genetic screening of Gre enlandic Inuit families with high risk for breast and/or ovarian cancer. (PubMed id 20437199)¹ Hansen T.V....Nielsen F.C. (2010)
1014. Polymorphisms in DNA repair genes and risk of non-Hod gkin lymphoma in a pooled analysis of three studies. (PubMed id 20813000)¹ Shen M....Zheng T. (2010)
1015. BRCA1 gene mutations may explain more than 80% of exc ess number of ovarian cancer cases after breast cancer - a population based stu dy from the Western Sweden Health Care region. (PubMed id 20151938)¹ Einbeigi Z....Karlsson P. (2010)
1016. Incorporating tumour pathology information into breas t cancer risk prediction algorithms. (PubMed id 20482762)¹ Mavaddat N....Antoniou A.C. (2010)
1017. Controversial BRCA1 allelotypes in commonly used brea st cancer cell lines. (PubMed id 19585236)¹ Karnan S....Konishi H. (2010)
1018. Toward classification of BRCA1 missense variants usin g a biophysical approach. (PubMed id 20378548)¹ Rowling P.J....Itzhaki L.S. (2010)
1019. RASSF1A polymorphism in familial breast cancer. (PubMed id 20361264)¹ Bergqvist J....Newman W.G. (2010)
1020. Identification of breast tumor mutations in BRCA1 tha t abolish its function in homologous DNA recombination. (PubMed id 20103620)¹ Ransburgh D.J....Parvin J.D. (2010)
1021. A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiat ion in rectal cancer. (PubMed id 20644561)¹ Ho-Pun-Cheung A....Lopez-Crapez E. (2010)
1022. UHRF1 is associated with epigenetic silencing of BRCA 1 in sporadic breast cancer. (PubMed id 19943104)¹ Jin W....Shao Z.M. (2010)
1023. Akt activation emulates Chk1 inhibition and Bcl2 over expression and abrogates G2 cell cycle checkpoint by inhibiting BRCA1 foci. (PubMed id 20495005)¹ Tonic I....Hay N. (2010)
1024. Aberrant methylation of breast and ovarian cancer sus ceptibility gene 1 in chemosensitive human ovarian cancer cells does not involv e the phosphatidylinositol 3'-kinase-Akt pathway. (PubMed id 20487263)¹ Wang Y.Q....Wan X.P. (2010)
1025. Mutation scanning of exon 20 of the BRCA1 gene by hig h-resolution melting curve analysis. (PubMed id 19747471)¹ Vorkas P.A....Lianidou E.S. (2010)
1026. Identification of the first case of germline duplicat ion of BRCA1 exon 13 in an Italian family. (PubMed id 20041308)¹ Cerutti R....Capella C. (2010)
1027. The role of BRCA1 in DNA damage response. (PubMed id 21203981)¹ Wu J....Yu X. (2010)
1028. Differential modulation of BRCA1 and BARD1 nuclear lo calisation and foci assembly by DNA damage. (PubMed id 19796682)¹ Brodie K.M. and Henderson B.R. (2010)
1029. BRCA1-mutated and basal-like breast cancers have simi lar aCGH profiles and a high incidence of protein truncating TP53 mutations. (PubMed id 21118481)¹ Holstege H....Jonkers J. (2010)
1030. Novel BRCA1/2 mutations in Serbian breast and breast- ovarian cancer patients with hereditary predisposition. (PubMed id 20804917)¹ DobriciA8 J....RaduloviA8 S. (2010)
1031. BRCA1 role in the mitigation of radiotoxicity and chr omosomal instability through repair of clustered DNA lesions. (PubMed id 20371364)¹ Hair J.M....Georgakilas A.G. (2010)
1032. BRCA1 regulation of base excision repair pathway. (PubMed id 20581465)¹ Saha T....Rosen E.M. (2010)
1033. An approach based on a genome-wide association study reveals candidate loci for narcolepsy. (PubMed id 20677014)¹ Shimada M....Tokunaga K. (2010)
1034. A critical re-appraisal of BRCA1 methylation studies in ovarian cancer. (PubMed id 20797776)¹ Senturk E....Martignetti J.A. (2010)
1035. Induction of breast cancer in wild type p53 cells by BRCA1-IRIS overexpression. (PubMed id 20845286)¹ Elshamy W.M. (2010)
1036. Occult ovarian cancers identified at risk-reducing sa lpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. (PubMed id 20180014)¹ Domchek S.M....Rebbeck T.R. (2010)
1037. Single-nucleotide polymorphisms in the p53 pathway ge nes modify cancer risk in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. (PubMed id 20306497)¹ Yarden R.I....Papa M.Z. (2010)
1038. Penetrance of breast cancer, ovarian cancer and contr alateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at ol der age. (PubMed id 20204502)¹ van der Kolk D.M....Oosterwijk J.C. (2010)
1039. A locus on 19p13 modifies risk of breast cancer in BR CA1 mutation carriers and is associated with hormone receptor-negative breast c ancer in the general population. (PubMed id 20852631)¹ Antoniou A.C....Couch F.J. (2010)
1040. Pathologic complete response rates in young women wit h BRCA1-positive breast cancers after neoadjuvant chemotherapy. (PubMed id 20008645)¹ Byrski T....Narod S. (2010)
1041. Broad BRCA1 and BRCA2 mutational spectrum and high in cidence of recurrent and novel mutations in the eastern Spain population. (PubMed id 20033483)¹ Esteban CardeA+osa E....MartA-nez de DueA+as E. (2010)
1042. Non-founder BRCA1 mutations in Russian breast cancer patients. (PubMed id 20727672)¹ Iyevleva A.G....Imyanitov E.N. (2010)
1043. Favourable ten-year overall survival in a Caucasian p opulation with high probability of hereditary breast cancer. (PubMed id 20219108)¹ Cortesi L....Federico M. (2010)
1044. Double heterozygosity in the BRCA1 and BRCA2 genes in the Jewish population. (PubMed id 20924075)¹ Lavie O....Rennert G. (2010)
1045. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients. (PubMed id 20215541)¹ Sanz D.J....Velasco E.A. (2010)
1046. Risk factors for non-invasive lesions of the fallopia n tube in BRCA mutation carriers. (PubMed id 20722102)¹ Vicus D....Narod S.A. (2010)
1047. Risk factors for non-invasive lesions of the fallopia n tube in BRCA mutation carriers. (PubMed id 20965088)¹ Vicus D....Narod S.A. (2010)
1048. Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. (PubMed id 20059483)¹ Skytte A.B....CrA1ger D. (2010)
1049. BRD7, a subunit of SWI/SNF complexes, binds directly to BRCA1 and regulates BRCA1-dependent transcription. (PubMed id 20215511)¹ Harte M.T....Harkin D.P. (2010)
1050. Derepression of HMGA2 via removal of ZBRK1/BRCA1/CtIP complex enhances mammary tumorigenesis. (PubMed id 20007691)¹ Ahmed K.M....Lee W.H. (2010)
1051. Comprehensive screen of genetic variation in DNA repa ir pathway genes and postmenopausal breast cancer risk. (PubMed id 20496165)¹ Monsees G.M....Han J. (2010)
1052. The molecular pathogenesis of hereditary ovarian carc inoma: alterations in the tubal epithelium of women with BRCA1 and BRCA2 mutati ons. (PubMed id 20665887)¹ Norquist B.M....Swisher E.M. (2010)
1053. Presymptomatic breast cancer in Egypt: role of BRCA1 and BRCA2 tumor suppressor genes mutations detection. (PubMed id 20579331)¹ Ibrahim S.S....Hashishe M.M. (2010)
1054. The AIB1 gene polyglutamine repeat length polymorphis m and the risk of breast cancer development. (PubMed id 20422428)¹ Kleibl Z....Pohlreich P. (2010)
1055. Preventing future cancers by testing women with ovari an cancer for BRCA mutations. (PubMed id 19841329)¹ Kwon J.S....Lu K.H. (2010)
1056. Lympho-vascular invasion in BRCA related breast cance r compared to sporadic controls. (PubMed id 20398395)¹ van Voss M.R....van Diest P.J. (2010)
1057. Bcr/Abl interferes with the Fanconi anemia/BRCA pathw ay: implications in the chromosomal instability of chronic myeloid leukemia cel ls. (PubMed id 21203397)¹ Valeri A....Bueren J.A. (2010)
1058. Common breast cancer susceptibility alleles and the r isk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for ri sk prediction. (PubMed id 21118973)¹ Antoniou A.C....Easton D.F. (2010)
1059. BRCA1-IRIS overexpression promotes cisplatin resistan ce in ovarian cancer cells. (PubMed id 20940403)¹ Chock K.L....ElShamy W.M. (2010)
1060. BRCA1 and BRCA2 genetic test in high risk patients an d families: counselling and management. (PubMed id 21042765)¹ Marchina E....Barlati S. (2010)
1061. Impact of androgen receptor cytosine-adenine-guanine polymorphisms on clinical outcome in BRCA mutation-associated epithelial ovaria n cancers. (PubMed id 19818997)¹ Li A.J....Karlan B.Y. (2010)
1062. Transcriptional regulation of BRCA1 expression by a m etabolic switch. (PubMed id 21102443)¹ Di L.J....Gardner K. (2010)
1063. Prevalence of BRCA1 and BRCA2 mutations in women with breast carcinoma In Situ and referred for genetic testing. (PubMed id 21149333)¹ Hall M.J....Wenstrup R.J. (2010)
1064. Cancer predisposing missense and protein truncating B ARD1 mutations in non-BRCA1 or BRCA2 breast cancer families. (PubMed id 20077502)¹ De Brakeleer S....Teugels E. (2010)
1065. BRCA1 mutations and colorectal cancer in Poland. (PubMed id 20862552)¹ Suchy J....Narod S.A. (2010)
1066. A BRCA1 promoter variant (rs11655505) and breast canc er risk. (PubMed id 20413709)¹ Verderio P....Peterlongo P. (2010)
1067. Identification of a Danish breast/ovarian cancer fami ly double heterozygote for BRCA1 and BRCA2 mutations. (PubMed id 20455026)¹ Steffensen A.Y....Hansen T.V. (2010)
1068. 'The bigger the network the bigger the bowl of c herries...': exploring the acceptability of, and preferences for, an ongoi ng support network for known BRCA 1 and BRCA 2 mutation carriers. (PubMed id 20411314)¹ Hughes L. and Phelps C. (2010)
1069. High penetrances of BRCA1 and BRCA2 mutations confirm ed in a prospective series. (PubMed id 20180971)¹ MA...MA (2010)
1070. Redox-dependent Brca1 transcriptional regulation by a n NADH-sensor CtBP1. (PubMed id 20818429)¹ Deng Y....Zhang Q. (2010)
1071. Copy number variations are not modifiers of phenotypi c expression in a pair of identical twins carrying a BRCA1 mutation. (PubMed id 20369283)¹ Lasa A....Baiget M. (2010)
1072. c-IAP1 and UbcH5 promote K11-linked polyubiquitinatio n of RIP1 in TNF signalling. (PubMed id 21113135)¹ Dynek J.N....Vucic D. (2010)
1073. Comprehensive BRCA1 and BRCA2 mutation analyses and r eview of French Canadian families with at least three cases of breast cancer. (PubMed id 20694749)¹ Cavallone L....Tonin P.N. (2010)
1074. Prevalence of BRCA1 and BRCA2 germ line mutations amo ng women with carcinoma of the fallopian tube. (PubMed id 20570322)¹ Vicus D....Narod S.A. (2010)
1075. Alternative splicing and molecular characterization o f splice site variants: BRCA1 c.591C>T as a case study. (PubMed id 19892845)¹ Dosil V....de la Hoya M. (2010)
1076. BRCA1/2 germline mutations in Jewish patients with ut erine serous carcinoma. (PubMed id 21206239)¹ Bruchim I....Fishman A. (2010)